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1.1 Enantiomer and its importance
1.1.1 Definitions and overview of isomers [1,2,3]
Isomers are compounds that have the same stoichiometric molecular formula but differ in
connectivity or spatial arrangement of their atoms. Isomers can be divided into two types;
constitutional or structural isomers and stereoisomers. Constitutional isomers have a different
connectivity or binding pattern of the atoms in three-dimensional space. For example, 1-propanol
and 2-propanol possess the same molecular formula C4H10O, but their binding patterns are
different (see Fig. 1). Stereoisomers have the same connectivity, but differ in the spatial orientation
of some or all atoms in the three-dimensional space. Stereoisomers that their structures can be
made identical by rotation around one or more single bonds are referred to conformational isomers.
Conformational isomers are not included in this thesis. Only Configurational isomers will be
described. Therefore, stereoisomers may be subdivided into two groups, i.e. enantiomers and
diastereomers.
Enantiomers are nonsuperimposable mirror images of each other. For example, R-2-bromobutane
and S-2-bromobutane have the same connectivity of their atoms, but the spatial arrangement of
their atoms in the space is different (Fig. 1). The enantiomers of 2-bromobutane are mirror images
but they cannot be superimposed. Nonsuperimposable mirror image is normally present in
molecules bearing an asymmetric carbon atom or a chiral atom. Chiral atom has tetrahedral
structures that are bonded by four different atoms or groups. In addition to the carbon atom, chiral
centers can also be found in other elements such as silicon, nitrogen, phosphorus or sulfur.
Compounds that their molecules are nonsuperimposable mirror image will be optically active. A
pair of enantiomer can rotate the plane of plane-polarized light in equal amount or degree of
rotation but in the opposite direction, so that enantiomers can also be classified as optical isomers
(see Fig. 1). A pair of enantiomers has essentially identical physical and chemical properties in
achiral media.
Diastereomers are stereoisomers that are not enantiomers. Thus, diastereomers are not related as
mirror image of each other. Moreover, diastereomers may not always optically active. Unlike
enantiomers, diastereomers generally have different physiochemical properties. Molecules having
two or more stereogenic centers and geometric isomers that their structures are not related as
mirror images are also considered to be diastereomers. The molecules bearing two or more
stereogenic centers may have identical configuration at one or more stereogenic centers but
opposite configuration at others. Geometric isomers possess molecules that have a restricted
rotation at normal room temperatures and pressures. Restricted rotation in the molecules can be
caused either by a double bond or a cyclic structure such as cis-1,2-dichloroethylene and trans-1,2-
dichloroethylene bearing a double bond in the molecules (see also Fig. 1).
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Figure 1. Overview of isomerism. (adapted from Ref. [1])
1.1.2 Enantiomers and biological activities
The stereoisomers play an important role in biological activity because of the stereospecificity for
active and receptor sites. The interactions between the biologically active compounds and receptor
proteins or enzymes often show a high or complete stereoselectivity. On the other hand, each
isomer may have a different affinity to enzymes and the active sites of the receptors resulting in a
different characteristic biological activity or toxicity. For example, while one enantiomer is active the
other one enantiomer may have [2];
- no activity, for example, S-(+)-ibuprofen is an anti-inflammatory drug, the R-(–)-
enantiomer has no activity,
- the same type and strength of the activity, for example, both the same isomers of the H
blocker promazine have the same activity,
- the same type of the activity but weaker potency, for example, the R-(+)-enantiomer of
the anticoagulant warfarin is less potent than the S-(–)-enantiomer,
- a different activity, for example, the S-(+)-enantiomer of ketamine is responsible for
most of its anesthetic action while the R-(–)-enantiomer is responsible for its psychotic
effects,
- a toxicity, for example, S-(–)-penicillamine is used as antiarthritic drug while R-(+)-
penicillamine is extremely toxic.
Isomers
Same stoichiometric molecular formula but different
constitution or arrangement of their atoms in space
Constitutional isomers
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Further examples of enantiomeric drugs that have different pharmacological and/or toxicological
properties are shown in Table 1.
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1.1.3 Enantiomers and drug development
In Table 1, the differences in drug action and/or toxicity of a pair of enantiomer are shown. One of
the most recognized examples of an undesirable effect due to the use of a racemic drug is
thalidomide. Thalidomide was synthesized in 1954 by Grünenthal Chemie in Germany under the
brand name of Countergan and was subsequently licensed in other 46 countries [5]. The drug was
first marketed in Germany in 1957 and was used as a sedative drug as well as an effective
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antiemetic in pregnancy [5, 6]. In 1961 thalidomide was withdrawn from the market due to the fact
that thalidomide caused teratogenic effects in pregnant women. Even through the cause of
teratogenic effect is yet unclear, some experiments in animals suggested that the teratogenic effect
may be caused by (S)-(–)-thalidomide [7–10]. The tragedy of thalidomide resulted in an awareness
of using the racemic drugs and a stricter control as well as a reconsideration of the guidelines for
new drug approval.
A new marketing strategy called racemic switch was launched due to the debates over racemic
compounds and single enantiomers. The racemic switch offers the opportunity to the industrial
companies to apply the single enantiomer compounds as new drugs even through their racemates
have already been approved. Therefore many pharmaceutical companies have started to
investigate the pharmacology and toxicology of individual enantiomers, and launch single pure
enantiomer drugs to the market. An increase in the number of the single enantiomer drugs that
were marketed from 2000 – 2005 is shown in Table 2. Moreover, Fig. 2 shows the proportions of
achiral drugs, racemic drugs and single enantiomer drugs from year 1988 – 2002 highlighting an
increase in the number of single enantiomer drugs in Japan.
Table 2. Worldwide sales of single enantiomer pharmaceutical products [11]








Cardiovascular 27,650 34,033 36,196 6
Antibiotics and antifungals 25,942 32,305 34,298 6
Cancer therapies 12,201 21,358 27,172 17
Hematology 11,989 20,119 22,439 13
Hormone and endocrinology 15,228 20,608 22,355 8
Central nervous system 9,322 17,106 18,551 15
Respiratory 6,506 12,827 14,708 18
Antiviral 5,890 11,654 14,683 20
Gastrointestinal 4,171 11,647 13,476 26
Ophthalmic 2,265 3,063 3,416 9
Dermatological 1,272 1,486 1,561 4
Vaccines 1,427 2,450 3,100 17
Other 7,128 10,400 13,268 13
Total 130,991 199,056 225,223 11
* CAGR is compound annual growth rate
Source: Technology Catalysts International
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Figure 2. Number of Drug Approved in Japan during 1988 – 2002 [12]
1.2 Enantiomeric purity and regulatory agencies
As mentioned above single enantiomer drugs have become an important part of the overall
pharmaceutical market. Generally, the safety and efficacy of the drug depend not only on the
pharmacological and toxicological data of the active ingredient itself but also on the impurities.
Therefore, the purity of stereoisomeric drug substances and products is an important issue. In the
United States, the Food and Drug Administration (FDA) has stated a policy for new drug
applications which requires appropriate information on the chemistry as well as the manufacturing
and control data, such as methods and specifications, results of stability tests, proper labeling,
pharmacological activity, pharmacokinetic profile, toxicology, and impurity limits [13]. For single
enantiomers, pharmacology and toxicology evaluations must be conducted relying on the existing
knowledge of the racemate. The European Medicines Agency (EMA) has stated guidelines on the
quality, safety, and efficacy of medicinal products for human use [14] which are similar to the FDA
guidelines. Besides the marketing considerations, the availability of single pure enantiomers is of
importance in order to facilitate the studies of pharmacokinetics, pharmacodynamics,
pharmacological and toxicological properties of single stereoisomeric compounds compared to
racemic drugs that will ensure the safety and efficacy of the drugs.
The nature and quantity of impurities in a drug substance depend on different factors including the
synthetic route, reaction conditions, quality of the starting material, reagents, solvents, purification
steps, excipients, drug product manufacturing processes, packaging, and storage of the end
product [15]. As a result by-products, intermediates and degradation products that are defined as
pharmaceutical impurities can be found in drug substances and products. A pharmaceutical
impurity is defined as any component of the drug substance or drug product that is not the active
pharmaceutical ingredient. Impurity profiling which is a description of the identity as well as the
quantity of impurities present in a drug substance or drug product is an important concern of the
regulatory authorities. Thus, impurity profiling includes analytical activities with the aim of the
detection, identification/structure elucidation and quantitative determination of organic and
inorganic impurities as well as residual solvents in bulk drugs and pharmaceutical formulations [16].
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In general, impurity limits (both specified and non-specified impurities) are listed in the monographs
of pharmacopeias, for example, the British Pharmacopoeia (BP), the European Pharmacopoeia,
the Japanese Pharmacopoeia and the United State Pharmacopeia (USP). The limits for related
impurities vary from drug to drug and monograph to monograph. In the case of “classical” drugs
usually 1.0-1.5% of total impurities and 0.5% of individual impurities are accepted. But in the case
of new monographs the tendency is to limit total impurities down to about 0.5%. Furthermore, the
International Conference on Harmonization (ICH) issued the regulations of impurities in new drug
substances (ICH Q3A) [17] and drug products (ICH Q3B) [18]. The impurities can be classified into
three groups based on ICH Q3A; organic impurities (process- and drug-related), inorganic
impurities, and residual solvents. All potential impurities present in the new drug substances at a
level greater than the reporting threshold (see Table 3) should be reported. Moreover, the
structures of impurities should be identified if the impurities present at a level greater than the
identification threshold. Identification of impurities present at an apparent level of not more than the
identification threshold is generally not considered necessary, except for impurities that are
expected to be unusually potent, producing toxic or pharmacological effects. Furthermore, if
impurities present at a level greater than the qualification threshold, the impurities should be
qualified for the biological safety. However, lower qualification thresholds can be appropriate if the
impurities are unusually toxic.









≤ 2g/day 0.05% 0.10% or 1.0 mg per day
intake (whichever is lower)
0.15% or 1.0 mg per day
intake (whichever is lower)
> 2g/day 0.03% 0.05% 0.05%
1 The amount of drug substance administered per day
2 Higher reporting thresholds should be scientifically justified
3 Lower thresholds can be appropriate if the impurity is unusually toxic
In addition, specific tests and acceptance criteria have been addressed in the ICH guideline Q6A
[19]. Regarding the ICH guideline Q6A on chiral drug substances which are developed as a single
enantiomer, control of the other enantiomer should be considered in the same manner as for other
impurities. Wherever the specified impurities, impurity limits and acceptance criteria listed in the
monographs of pharmacopoeias are appropriate, they have to be utilized.
1.3 Separation and determination of enantiomeric impurities in drug substances
Since pairs of various enantiomers have been shown to have different therapeutic and toxicological
properties, the identification and quantification of stereochemical impurities in raw materials and/or
drug substances are an important part of drug development and regulatory assessment. The ICH
guideline Q3A [17] recommended that the registration application for new drug substances should
include documented evidence that the analytical procedures are validated and suitable for the
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detection and quantification of impurities. The separation and determination of an enantiomeric
impurity in drug substances can be accomplished by the “traditional” method polarimetry and
modern methods including chiral high-perfomance liquid chromatography (HPLC) and chiral
capillary electrophoresis (CE).
Traditional methods including the use of optical rotation often proved to be inadequate for the
determination of enantiomeric impurities. However, polarimetry is still the simplest and most
universal technique available to determine enantiomeric purity [20]. The main disadvantage of
polarimetric method is that it requires knowledge of the specification of an optically pure sample
and relatively large amounts of the substance are required for the quantification. Moreover, some
chiral substances yield a small optical rotation and in such a situation the sensitivity of the
polarimetric method is low. Therefore, the change in optical rotation as a function of concentration
is small and can lead to a mistake in quantification.
Among chromatographic methods chiral HPLC is the most widely used as the analysis for
enantioseparation because of a sufficient sensitivity, a wide variety of commercial columns, and of
extensive application literatures [21]. The separation in HPLC can be performed by indirect
separation using chiral derivatization reagents or by direct separation employing chiral stationary
phases or chiral mobile phase additives. The indirect separation is based on the use of chiral
derivatization reagents to form diastereomeric derivatives which differ in their chemical and
physical properties and therefore can be separated on achiral stationary phases. The indirect
separation is an alternative to an expensive chiral column and to compounds without a
chromophore. It is more flexible, but the derivatization represents an additional step which can
involve undesirable side reactions, the formation of decomposition products and recemization of
chiral-derivertizing reagents [22, 23]. Moreover, the chiral derivatization reagents have to be of high
enantiomeric purity and the presence of derivatizable groups in the analyte is a prerequisite. The
direct approach using columns with chiral stationary phase is more convenient and also applicable
for separations on a preparative scale. However, a collection of expensive columns to solve a
variety of problems is required. The chiral mobile phase additive approach is a simple and flexible
alternative which is not always applicable. The main disadvantage of chiral mobile phase additive is
the high UV background noise if a chiral selector is UV absorbing. Moreover, the retention of the
analyte may be difficult to predict and since the mobile phase contains the chiral selector it cannot
be reused. Furthermore, relatively large amounts of the chiral selector are required.
Over the last two decades capillary electrophoresis (CE) has been acknowledged as a powerful
analytical technique for chiral separations. It has become an alternative method to the
chromatography, especially chiral HPLC, due to its simplicity, reliability, versatility, and low
consumption of sample, chiral selector and reagents [24–29]. Moreover, CE has been employed as
a suitable analytical method for drug-related impurity determinations in the routine laboratory [30].
The differences between HPLC and CE used as chiral separation techniques are compared and
described in Table 5 which shows many advantages of using CE over HPLC. In recent years many
fully validated CE methods have been described and CE is becoming a well established technique
in academia as well as in the pharmaceutical industry [31]. Overall, CE with variety modes has
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become one of advanced analytical methods for drug analysis in pharmaceutical, therapeutic,
diagnostic as well as forensic applications as documented in many reviews [29, 32–37].












Expensive columns, consumption of
a relatively high amount of buffer
solutions, and hazardous organic
modifiers.
Immobilized; great number of
commercially available CSPs; a
combination of chiral selectors is
difficult or at least time-consuming.
Chiral separation selectivity may in
the best case approach the
thermodynamic selectivity of the
chiral recognition but will never
exceed it; the separation efficiency
sometimes is poor.
Impossible to adjust the selectivity of
chiral separation without changing
the affinity pattern of the
enantiomers toward chiral selector.
Semi-preparative and preparative
scale.
Relatively slow; changing and
conditioning a column is time-
consuming.
Simple instrument: no pump, injector
valves, and detector cells are
required; a minute amount of solvent
and extremely low amount of chiral




available chiral selector are
inexpensive, chiral selectors can be
mixed in any desired ratio (only
limited by solubility).
Separation selectivity may easily
exceed the thermodynamic
selectivity of the recognition; a chiral
separation even in the absence of
chiral recognition is, in principle,
feasible; high peak efficiency.
Possible to adjust the enantiomer
migration order without reverting the
affinity pattern between enantiomers
of the analyte and a chiral selector.
Analytical scale, very small sample
volumes.
Rapid; changing a capillary and/ or




The scheme of a CE instrument is shown in Fig. 3. The instrumental consists of a
hydrodynamic/electrokinetic sample introduction (not shown), a voltage supply, a detector, an
electrode, a buffer reservoir, and a capillary. Upon applying voltage to the capillary the migration
and separation occur depending on the electric charge of the analytes. Anions migrate to the
anode while the cations migrate to cathode by their electrophoretic mobility (ep). In untreated
fused-silica capillaries, the electric double layer formed at the interface between the solid inner wall
and the buffer solution (liquid phase) generates an electroosmotic flow (EOF) after an application of
an electric field. The total mobility of analytes depends on the sum of the EOF and the (effective)
electrophoretic mobilities of the analytes. The difference in mobility depends on charge density of
compounds under specific conditions [39]. Under normal polarity of the applied voltage the EOF is
directed toward the cathode.
Figure 3. Schematic drawing of instrument CE consisting of a voltage supply (1), a detector (2), an
electrode (3), a buffer reservoir (4), and a capillary (5). (modified from Ref. [39])
There are several modes and miscellaneous techniques of CE such as capillary zone
electrophoresis (CZE), micellar electrokinetric chromatography (MEKC), microemulsion
electrokinetic chromatography (MEEKC), capillary isoelectric focusing (CIEF), capillary gel
electrophoresis (CGE), capillary isotachophoresis (CITP) and capillary electrochromatography
(CEC). The modes used in this thesis are briefly discussed below;
1.4.1 Capillary zone electrophoresis (CZE)
CZE is essentially high voltage electrophoresis in free solution. The capillary is filled with the
running buffer solution and the ionic analytes are separated under high electric fields (hundreds of
volts per centimeter) on the basic of their electrophoretic mobility [25]. The electrophoretic
migration velocity (v) of a charged analyte depends on its electrophoretic mobility ( e ) and on the



















with q = ion charge; r = ion radius;  = solution viscosity.
Besides the electrophoretic migration, electroosmosis (EOF) which is directed from the anodic to
the cathodic end of an untreated fused-silica capillary is a fundamental factor in CZE. The






where  = dielectric constant of the solvent, and = zeta potential at the capillary wall.
The EOF is affected by experimental conditions, for example, buffer pH (affecting the dissociation
of the wall silanols), ionic strength (affecting the zeta potential), organic solvents (affecting both
zeta potential and buffer viscosity), and buffer additives (e.g. surfactants, methyl cellulose,
polyacryamide, quaternary amines) [25].
1.4.2 Cyclodextrin-mediated capillary electrophoresis
Cyclodextrin-mediated CE is most widely used for the separation of enantiomers. There are several
chiral selectors used for enantioseparation, such as cyclodextrins, chiral crown ethers, linear oligo-
and polysaccharides, proteins, macrocyclic antibiotics, chiral calixarenes, chiral synthetic polymers,
and molecularly imprinted polymers. However, cyclodextrins (CDs) with a wide variety of its
derivatives are the most frequently used in chiral CE [40, 41]. Cyclodextrins are cyclic, non-
reducing oligosaccharides consisting of D-glucopyranose units bonded through α-1,4-linkages. The
smallest non-derivatized CD is the α-CD (containing six glucose units), followed by β-CD (seven
glucose units), and γ-CD (eight glucose units), respectively. CDs have a hydrophobic interior cavity
and a hydrophilic outside due to the hydroxyl groups. The structures of native α-, β- and γ-CD with
a similar shape to a truncated cone are shown in Fig. 4. The narrow rim of the CDs has the primary
hydroxyl groups at C6 and the wider rim contains the secondary hydroxyl groups at C2 and C3.
Figure 4. Molecular dimensions (d/nm) and structures of α-, β- and γ-CD (from Ref. [42])
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Due to the limited capability of native CDs to resolve all enantiomers of interest CD derivatives
have been increasingly used. Various functional groups have been utilized yielding neutral,
negatively charged, positively charged, amphoteric and polymerized CD derivatives. Examples of
commercial CD derivatives are listed in Table 6.
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SO3Na in position 6
CH3CO in positions 2 and 3, SO3Na in position 6
CH3 in positions 2 and 3, SO3Na in position 6




















1.4.3 Theoretical background of chiral separations in capillary electrophoresis
Chiral recognition occurs due to the difference in the stereoconfigurations of enantiomers resulting
in a different binding to the CDs. CDs containing a hydrophobic cavity are able to form inclusion
complexes with analytes. Moreover, the hydroxyl groups or other substituents on the rim of CDs
can also interact with the analytes. The temporary complexes between chiral selectors and
enantiomers are stabilized by number of intermolecular interactions. The most important
interactions are hydrogen bonding,   , dipole-dipole or ionic interactions. However, weaker
interactions such as van der Waals interactions and charge transfer may also be important for
chiral recognition mechanisms.
A theoretical model has been developed [44, 45] in order to explain the enantiomer separations in
CE. In most cases it is assumed that there is a 1:1 interaction between a pair of enantiomers (R
and S) and a chiral selector (C) as shown in Fig. 5.
Figure 5. Schematic model of the complexation equilibrium between uncomplexed enantiomers,
the chiral selectors and the enantiomer-chiral selector complexes.
The equation that allows the determination of the mobility difference,  , between two
enantiomers can be written as follows [29, 44–46]:






















where R  and S are the observed mobilities of the R and S enantiomers, respectively, f  is the
mobility of the analyte enantiomers in the umcomplexed form, RK  and SK  are the complexation
equilibrium constants of the R and S enantiomers with the chiral selector, cR  and cS are the
mobilities of the respective temporary diastereomeric complexes between the chiral selector and
the R and S enantiomers, and [C] is the concentration of the chiral selector. While the mobilities of
the uncomplexed enantiomers are identical, the equilibrium constants or the mobilities of temporary
diastereomeric complexes may be different. The prerequisite for enantioseparations in CE is that
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0 (6)
Regarding the equation 5, an enantioseparation in CE can be achieved either by the differences
between the binding constants (or the affinities) of the enantiomers with a chiral selector
( SR KK  ) or the differences between the mobilities of the temporary diastereomeric complexes
( cScR   ). A combination of both cases may also apply.
1.4.4 Microemulsion electrokinetic chromatography (MEEKC)
The microemulsions (MEs) are macroscopically homogeneous, optically transparent fluids which
consist of more than one liquid phase. Generally, the microemulsion system is composed of an oil
core or a lipophilic organic solvent, surfactants (such as sodium dodecyl sulfate (SDS)) which are
used to stabilize the microemulsion droplet by lowering the surface tension between the two liquid
phases, and/or co-surfactants (i.e. short-chain alcohol) which position themselves between the
head groups of the surfactant molecules reducing the electrostatic repulsion. There are two
principal types of MEs; an oil-in-water (O/W) ME representing the bulk phase that is made up by
water and the oil are dispersed in water phase, while a water-in-oil (W/O) ME is where the bulk
phase is made up by oil. In MEEKC microemulsion droplets are used as pseudostationary phases
(PSPs). MEEKC was introduced for the separation of very lipophilic substances as well as
hydrophilic substances as reviewed in [33, 47–49].
Chiral separations in MEEKC can be achieved by the use of chiral surfactants, chiral oil cores or by
the addition of chiral selectors such as CDs to a microemulsion. The use of CDs in MEEKC also
called “Cyclodextrin-modified microemulsion electrokinetic chromatography (CD-modified
MEEKC)” can enhance the solubility of hydrophobic compounds, the enantioseparation of both
charged and uncharged compounds as well as the resolution of the analytes. Fig. 6 shows the dual
partitioning mechanisms between the CDs as a chiral selector and microemulsion droplets as a
second pseudostationary phase resulting in a separation of both hydropillic and hydrophobic
compounds.




1.4.5 Factors affecting cyclodextrin-mediated stereoisomer separations
There are several factors that affect the stereoisomer separations such as CD type and
concentration, pH and ionic strength of the background electrolyte (BGE), addition of organic
solvents as well as temperature [51]. These factors are very important in order to achieve the
enantiosepartion and improve the enantioresolution. The factors are briefly described as follows.
 Type of CD
Most of CD derivatives are randomly substituted differing in the degree of substitution or in
the position of the substituents. Therefore, the chiral recongnition mechanism can hardly
be predicted. Moreover, the problems related to batch-to-batch variability of CDs may
occur with regard to poor reproducibility of the analytical methods.
 CD concentration
The influence of CD concentration on the enantioseparation of the analytes depends on
the charge of both the CDs and the analytes. For example, the mobilities of the neutral
analytes increase with the increasing of the charged CD concentration. While increasing
the neutral CD concentration the mobilities of charged analytes are decelerated. In case of
both analytes and CDs are charged the mobilities increase if both species carry the same
charge, while a decrease of mobilities or a reversal of the migration order is observed if
both species exhibit different charges.
 The pH of backround electrolyte (BGE) and ionic strength
The pH of BGE containing ionizable CD derivatives determines the effective net charge
and the effective mobility of the complexes. Moreover, the pH affects the ionization of
analytes which can influence the interaction between CDs and analytes as well as between
the capillary wall and analytes. Therefore, the pH will affect the migration times, the shape,
and the efficiency of the analytes’ peaks. The pH also affects the magnitude and the
direction of the EOF which can affect the apparent selectivity and the enantioseparation.
An increase in ionic strength reduces the electromigration dispersion, resulting in higher
separation efficiency. However, high BGE concentrations can lead to a high background
current and possibly to excessive Joule heating which may lead to the loss of selectivity
and efficiency.
 The addition of organic solvents
The presence of an organic solvent in the BGE can strongly influence the binding constant,
the migration times, the BGE conductivity, and the solubility of both analytes and CDs [40].
Moreover, the addition of an organic solvent may affect the effective selectivity depending
on the used CD concentration, for example, when the CD concentration is higher than its
optimal value the addition of an organic solvent to decrease the complexation constants
can consequently improve the selectivity values.
 Temperature
An increase in the temperature generally impairs the enantioselectivity [40]. However,
unusual temperature effects on enantioseparations were also observed. In some cases an
increase in temperature results in an improvement of enantioselectivity.
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1.5 Scopes and aims
Enantiomers often differ in potency, pharmacological activity or toxicological properties due to their
stereospecific interactions within biological systems. Consequently, single enantiomer drugs have
been increasingly investigated and have become an important part of the overall pharmaceutical
market. Thus, the safety and efficacy of a drug depend not only on the active ingredient itself but
also on the impurities including enantiomeric impurities. Therefore, the control of enantiomeric
purity as well as the impurity profiling of drug substances and products is an important concern of
the pharmaceutical companies and regulatory authorities.
Traditionally, the enantiomeric purity is determined by optical rotation in pharmacopeias such as
the European Pharmacopoeia or the United States Pharmacopeia. However, this method is error
prone especially in the case of a low specific rotation of the analyte. In modern monographs, chiral
HPLC assays have been introduced for the determination of the enantiomeric composition while
related substances are determined in an achiral HPLC test. In recent years CE has been
recognized as a microanalytical technique that is able to separate closely related compounds as
well as stereoisomers. Moreover, several CE modes are available allowing the analysis of
essentially any analyte. Thus, the aim of the thesis was:
- Development and validation of CE assays for the simultaneous analysis of the enantiomeric
purity of drug substances as well as the analysis of related substances. The single enantiomer
drugs dexamphetamine and levodopa as well as the racemic drug chloroquine served as model
compounds.
- Application of different modes of CE such as CZE and MEEKC for the chiral analysis.




In Chapter II the following five publications are described. The impurity profiling of
levoamphetamine and potential charged impurities in dexamphetamine sulfate was described in
Manuscript I. In Manuscript II, a CE assay employing a dual CD system was developed for the
simultaneous determination of charged and neutral impurities in dexamphetamine sulfate. An
alternative CE assay employing CD-modified MEEKC for the impurity profiling of dexamphetamine
sulfate was described in Manuscript III. The development and validation of a CE assay for
determination of levodopa and the R-enantiomer as well as related substances were described in
Manuscript IV. Manuscript V described the development and validation of a CE assay for the




Profilling of levoamphetamine and related substances in dexamphetamine sulfate by capillary
electrophoresis
Nino G. Kokiashvili, Sudaporn Wongwan, Carina Landgraf, Kristin Michaelis, Manuela
Hammitzsch-Wiedemann, Gerhard K.E. Scriba, Journal of Pharmaceutical and Biomedical Analysis
2009, 50, 1050–1053.
In this publication a CE assay for the simultaneous determination of the enantiomeric purity of
dexamphetamine as well as potential charged impurities, 1R,2S-(–)-norephedrine and 1S,2S-(+)-
norpseudoephedrine, was developed and validated. Several native cyclodextrins as well as neutral
and charged cyclodextrins such as -CD, 2-hydroxypropyl--CD, 2,6-dimethyl--CD, 2,3,6-
trimethyl--CD, carboxymethyl--CD, succinyl--CD, sulfated--CD and heptakis-(2,3-di-O-acetyl-
6-O-sulfo)--CD (HDAS--CD) were evaluated. HDAS--CD was selected for the method
development because of the better peak shape was obtained and the fact that HDAS--CD was a
single isomer derivative, so that the batch-to-batch reproducibility will not affect the performance of
the assay. The CD concentration, the buffer concentration and the buffer pH were subsequently
varied in order to achieve acceptable resolutions and peak shapes of all analytes when the sample
contained 2.0 mg/mL of dexamphetamine sulfate. Thus, the optimized background electrolyte
consisted of a 100 mM phosphate buffer, pH 2.5, containing 10 mg/mL of HDAS--CD. The
separation of the analytes was achieved in a 51/46.5 cm, 50 m id fused-silica capillary at a
temperature 20ºC and an applied voltage 25 kV. Detection was carried out at 205 nm. 1R,2S-(–)-
ephedrine was used as internal standard. The optimized method was subsequently validated
according to the ICH guideline Q2(R1) [52] with regard to linearity, range, limit of detection (LOD),
limit of quantitation (LOQ) as well as intraday and interday precision. The LOQ of all analytes was
1.2 g/mL (0.06%) and the LOD was 0.4 g/mL (0.02%) for 1R,2S-(–)-norephedrine and 1S,2S-(+)-
norpseudoephedrine, and 0.6 g/mL (0.03%) for levoamphetamine. Correlation coefficients of at
least 0.995 were obtained and RSD values of intraday and interday precision were below 7% for all
compounds. The assay was subsequently applied for the analysis of commercial dexamphetamine
sulfate drug substances. Neither 1R,2S-(–)-norephedrine nor 1S,2S-(+)-norpseudoephedrine could
be detected while levoamphetamine at concentrations between 2.8% and 4.0% was found in all
samples. The studies indicated that the drug substances were obtained by fractionated
crystallization of racemic amphetamine. The present stereoselective CE assay was also compared
to the determination of optical rotation according to the pharmacopeial tests of the USP 32 [53] and
the BP 2009 [54] by investigating enantiomeric purity of the same dexamphetamine sulfate sample.
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Manuscript II
CE assay for simultaneous determination of charged and neutral impurities in dexamphetamine
sulfate using a dual CD system
Sudaporn Wongwan, Bunleu Sungthong, Gerhard K.E. Scriba, Electrophoresis 2010, 31, 1475–
1481.
The objective of the study was to develop and validate a stereoselective CE assay for the
simultaneous determination of both charged and neutral impurities in dexamphetamine sulfate. As
none of the charged impurities could be detected in commercial samples (see manuscript I), it was
hypothesized that dexamphetamine was synthesized from phenylacetone (1-phenyl-2-propanone,
benzyl methyl ketone) via Leuckart reaction or by reduction of the oxime. Various negatively
charged CDs, e.g., sulfated -CD, sulfated -CD, sulfated -CD, heptakis-(2,3-di-O-acetyl-6-O-
sulfo)--CD, carboxymethyl--CD, carboxymethyl--CD, sulfopropyl--CD, sulfopropyl--CD and
sufobutylether--CD (DS 5) were initially investigated for their ability to separate the enantiomers of
amphetamine and the neutral impurities. High enantioresolution of amphetamine could be achieved
by employing sulfated -CD, but the neutral analytes migrated slowly and the peaks were rather
broad. A baseline separation with an acceptable peak shape was achieved by applying SBE(V)--
CD in the BGE. However, the resolution of enantiomers of amphetamine was poorer than the
sulfated -CD. Therefore, a dual CD system comprising sulfated -CD for the effective resolution of
the amphetamine enantiomers and SBE(V)--CD for the separation of phenylacetone and
phenylacetone oxime was selected. The effect of CD concentrations as well as the degree of
substitution (DS) of sulfobutylether--CD (DS = 4, 5 and 7) to the peak separation and peak shape
was studied. Besides, the effective length of the capillary, the applied voltage and the buffer pH
were subsequently optimized. The optimized conditions employed a 50 mM phosphate buffer, pH
3.0, contaning 80 mg/mL of SBE(V)--CD and 25 mg/mL sulfated -CD as background electrolyte,
a 50 m id fused-silica capillary with an effective length of 35 cm (total length 40.2 cm) at an
applied voltage –10 kV operated at 20ºC. The optimized assay also allowed the separation of the
E,Z-stereoisomers of phenylacetone oxime. The optimized method was subsequently validated
according to the ICH guideline Q2(R1) [52]. 1R,2S-(–)-ephedrine was used as internal standard.
The LOQ was 0.05% (2.5 g/mL) for all potential impurities. Correlation coefficients of at least
0.993 were observed and RSD values of intraday and interday precision were below 8% for all
compounds. The method was subsequently applied to the analysis of commercial samples of
dexamphetamine sulfate. Levoamphetamine could be detected in all samples at concentrations
between 3.2% and 3.7%. Neither 1R,2S-(–)-norephedrine nor 1S,2S-(+)-norpseudoephedrine
could be detected. In contrast, peaks corresponding to phenylacetone and both isomers of E,Z-




Impurity profiling of dexamphetamine sulfate by cyclodextrin-modified microemulsion electrokinetic
chromatography
Sudaporn Wongwan, Gerhard K.E. Scriba, Electrophoresis 2010, 31, 3006–3011.
Since the simultaneous application of MEEKC to the determination of achiral impurities of drugs
and the analysis of enantiomeric impurities has not been report to date, the study was conducted in
order to evaluate CD-modified MEEKC for the determination of stereoisomeric purity as well as
impurity profiling of drugs. Dexamphetamine sulfate and its impurities were selected as an example
due to the diversity of analytes comprising charged and uncharged analytes, chiral and achiral
analytes and a piar of enantiomers as well as another pair of E- and Z-geometrical isomers. The
microemulsion containing sodium dodecyl sulfate (SDS), ethyl acetate, 1-butanol, 2-propanol and a
50 mM sodium phosphate buffer was evaluated. Sulfated -CD was initially selected as the chiral
selector due to its wide commercial available and a relatively inexpensive. Composition of the
microemulsion, the CD concentration, the buffer concentration, the buffer pH and the applied
voltage were varied in order to achieve the baseline separation of all analytes. Moreover, the effect
of SDS, ethyl acetate, 1-butanol, 2-propanol and sulfated -CD on peak resolution and peak shape
was investigated. During method development, it was observed that preparation of the
microemulsion affected the separation between dexamphetamine and levoamphetamine as well as
between phenylacetone E-oxime and 1S,2S-(+)-norseudoephedrine depending on the addition of
sulfated -CD either before or after the preparation of the microemulsion. Amino acids and their
derivatives as well as structurally not related compounds, carbamazepine, were screened. Finally
carbamazepine was selected as an internal standard due to the peak shape and short migration
time. The optimized method employed a background electrolyte  containing 1.5% w/w SDS, 0.5%
w/w ethyl acetate, 3.5% w/w 1-butanol, 2.5% w/w 2-propanol and 92% w/w 50 mM phosphate
buffer, pH 3.0, containing 5.5% w/w sulfated -CD. The separations were carried out in a 50 m id
fused-silica capillary with an effective length of 40 cm (total length 50.2 cm) at an applied voltage
–14 kV and at a temperature of 20ºC. Subsequently, the method was validated according to the
ICH guideline Q2(R1) [52]. The LOQ estimated at a signal-to-noise ratio of 10 was 0.1% (3 g/mL)
for all potential impurities except for the Z-oxime with a LOQ of 0.5% (15 g/mL). Correlation
coefficients of at least 0.994 were observed and RSD values of intraday and interday precision
were below 8.2% for all compounds. Four commercial samples of dexamphetamine were
subsequently analyzed employing the validated method. Levoamphetamine was detected in all




Determination of related substances of levodopa including the R-enantiomer by CE
Sudaporn Wongwan, Manuela Hammitzsch-Wiedemann, Gerhard K.E. Scriba, Electrophoresis
2009, 30, 3891–3896.
Levodopa is described in monographs in the European Pharmacopoeia [55] and the United State
Pharmacopoeia (USP) [53]. The related substances specified by both pharmacopeias include L-
tyrosine, 3-methoxy-L-tyrosine, and 6-hydroxy-DOPA (6-OH-DOPA). In the European
Pharmacopoeia, different HPLC assays are required for the determination of related substances
and enantiomeric purity, while the USP prescribed a HPLC assay for the determination of related
substances and a polarimetric method for the determination of enantiomeric purity. However, as
none of the simultaneous assay had been reported, a stereoselective CE assay for the
simultaneous determination of related substances as well as the enantiomers of DOPA was
developed and validated. Sulfated -CD was selected as chiral selector in the present study. The
background electrolyte containing 2 mg/mL, 4 mg/mL, 6 mg/mL and 8 mg/mL sulfated -CD and a
0.12 M sodium phosphate buffer, pH 2.0, was evaluated. Subsequently, the buffer concentration,
buffer pH, applied voltage and effective length of the capillary were varied in order to achieve the
baseline separation of all analytes as well as acceptable peak shapes and short migration times. It
was observed that substituting the sodium phosphate buffer with a phosphate buffer prepared from
orthophosphoric acid and sodium hydroxide solution the buffer molarity and the concentration of
sulfated -CD could be reduced with a comparable peak resolution. Due to the fact that sulfated -
CD used in this study is a randomly substituted CD derivative which may hamper the reproducibility
of the assay, other two different batches from the other suppliers were investigated. Clearly,
different batches of sulfated -CD affected the separation, especially the critical resolution between
levodopa and L-tyrosine. The optimized conditions employed a 0.1 M phosphate buffer, pH 2.0,
prepared from orthophosphoric acid and sodium hydroxide solution containing 6 mg/mL sulfated -
CD as background electrolyte, a 50 m id fused-silica capillary with an effective length of 35 cm
(total length 45.2 cm), an applied voltage of 20 kV and 18ºC capillary temperature. The optimized
conditions also allowed the separation of the enantiomers of 6-OH-DOPA. The optimized method
was subsequently validated according to the ICH guideline Q2(R1) [52]. L-Phenylalanine was used
as internal standard. The LOQ was 0.1% (2 g/mL) for all impurities. Correlation coefficients of at
least 0.990 were observed and RSD values of intraday and interday precision were below 10% for
all compounds. Three samples of commercial levodopa drug substance were subsequently
analyzed. Neither 6-OH-DOPA nor 3-methoxy-L-tyrosine could be detected in all samples, whereas
L-tyrosine was detected in all samples but the quantities were below the LOQ. D-DOPA could be
detected in two samples, sample one had a quantity of D-DOPA below the LOQ, while another one
which is the reference substance of the European Pharmacopoeia an amount of D-DOPA up to
0.15 ± 0.01% could be detected.
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Manuscript V
Development and validation of a capillary electrophoresis assay for the determination of
stereoisomeric purity of chloroquine enantiomers
Sudaporn Wongwan, Gerhard K.E. Scriba, submitted manuscript.
Chloroquine is commercially available in a racemic mixture. The study of stereoselective biological
activities as well as toxicities of chloroquine enantiomers is still incomplete. Therefore, the
availability of pure enantiomers of (+)- and (–)-chloroquine is important. A stereoselective CE assay
was developed and validated in order to determine the enantiomeric purity of R-(–)-chloroquine
substance. Initial background electrolytes containing 5 mg/mL, 10 mg/mL, 20 mg/mL, and 30
mg/mL sulfated -CD and a 50 mM phosphate buffer, pH 2.5, were evaluated. Applying normal
polarity none of analytes could be detected. In contrast, all analytes could be detected with
reversed polarity of the applied voltage. However, the peaks were rather broad. Subsequently, the
buffer concentration was increased from 50 mM to 100 mM resulting in sharp peaks. Upon injecting
a sample containing 2 mg/mL of R-(–)-chloroquine and 20 g/mL of S-(+)-chloroquine peak
deformation of S-(+)-chloroquine was detected. Thus, background electrolytes containing SBE(V)-
-CD (DS ≈ 4.9) and SBE(VII)--CD (DS ≈ 6.6) were subsequently investigated. The separation as
well as acceptable peak shapes could be achieved by employing the background electrolyte
containing 30 mg/mL SBE(VII)--CD and the reversed polarity, whereas SBE(V)--CD was
insufficient. Migration order reversal of chloroquine enantiomers was observed when sulfated -CD
was substituted with SBE(VII)--CD. The optimized method employed a 100 mM sodium
phosphate buffer, pH 2.5, containing 30 mg/mL SBE(VII)--CD as the background electrolyte, a 50
m id uncoated fused-silica capillary with an effective length of 40 cm (total length 50.2 cm), an
applied voltage of -25 kV and 20°C capillary temperature. The optimized method was subsequently
validated according to the ICH guideline Q2(R1) [52]. Carbamazepine was used as internal
standard. Method validation was performed with racemic chloroquine because enantiomerically
pure chloroquine was not available. The LOQ was 0.05% (1.5 g/mL) for individual enantiomers
based on a concentration of 3 mg/mL of a major compound. Correlation coefficients of at least
0.997 were observed and RSD values of intraday and interday precision were below 6% for all
compounds. The sample of R-(–)-chloroquine substance was analyzed using the validated method.
S-(+)-chloroquine at levels 0.24% ± 0.01% (means ± SD) was observed in R-(–)-chloroquine.
Moreover, an unknown peak which migrated faster than the enantiomers was also detected at
0.4% level computed from the normalized peak area.
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Manuscript I
Profilling of levoamphetamine and related substances in dexamphetamine sulfate by capillary
electrophoresis
Nino G. Kokiashvili, Sudaporn Wongwan, Carina Landgraf, Kristin Michaelis, Manuela
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A stereoselective CE assay for the determination of the enantiomeric purity determination of R-(–)-
chloroquine and S-(+)-chloroquine was developed and validated. The separations were performed
in a 50/40.2 cm uncoated fused-silica capillary at 20°C using a 100 mM sodium phosphate buffer,
pH 2.5, containing 30 mg/mL sulfobutylether(VII)--cyclodextrin as background electrolyte operated
at an applied voltage of –25 kV and 20°C. The detection wavelength was 225 nm. Carbamazepine
was used as internal standard. The assay was validated in the range of 0.05 - 1.0 % for the
respective minor chloroquine enantiomer based on a concentration of 3 mg/mL of the major
enantiomer, either R-(–)-chloroquine or S-(+)-chloroquine. The method was applied to analyze the
stereoisomeric purity of synthetic samples of the chloroquine enantiomers.
Keywords: Chloroquine, Capillary electrophoresis, Cyclodextrin, Enantiomeric purity, Impurity
profiling
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1.   Introduction
Chloroquine (7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline, Figure 1) is a widely used
chemotherapeutic drug for the prophylaxis and the treatment of malaria [1-3]. The drug is active
only against the intra-erythocytic forms of the life cycle of the Plasmodium parasite. Although the
molecular mechanism of the antischizontal activity is not yet completely understood it appears to
be associated with the interaction between heme and chloroquine [1, 2, 4]. Heme polymerization in
the food vacuole of the parasite is inhibited by complexation of chloroquine by heme leading to the
accumulation of toxic heme. Furthermore, there is evidence that the formation of the heme-
chloroquine complex inhibits the catalase activity of heme resulting in accumulation of H2O2 and an
increased oxidative stress which can lead to damage of lipids and proteins. Chloroquine has also
been used as an anti-inflammatory drug for the treatment of rheumatoid arthritis [5, 6].
Chloroquine is commercially available as racemate. While there is no significant difference of the
activity of the individual enantiomers against Plasmodium falciparum in vitro [7], differences in the
antimalarial activity and toxicity of the enantiomers have been reported in vivo [8, 9]. This may be
due to stereoselective metabolism of the drug. Furthermore, the enantiomers appear to be less
embryotoxic compared to the racemate [10]. Due to these controversial data it appears desirable to
further study the enantioselective effects of the drug. Such efforts unequivocally require suitable
assays for the determination of the purity of the enantiomers of the compound.
The analytical separation of the chloroquine enantiomers has been achieved by HPLC using a
chiral stationary phase containing 1acid glycoprotein [11, 12] or heparin as chiral selector [13].
Capillary electrophoresis (CE) has become a powerful analytical microseparation technique in
recent years that is especially suited for enantioseparations [14-19]. The CE enantioseparation of
chloroquine has been achieved in the presence of various CDs as chiral selectors including
sulfated -CD [20-22], sulfobutylether--CD (SBE--CD) [23] or a mixture of -CDs [24].
Furthermore chloroquine enantioseparations in the presence of the polysaccharide colominic acid
[25], human serum albumin [26] and arsenyl-L-(+)-tartrate [27] have been published. However,
none of the CE assays has been used for the determination of the stereoisomeric purity of the
chloroquine enantiomers. Therefore, the aim of the present study was to develop and validate the
stereoselective CE assay for the determination of synthetic chloroquine enantiomers.
2.   Materials and methods
2.1 Chemicals
All chemicals were of analytical grade. Chloroquine diphosphate, carbamazepine, sulfated -
cyclodextrin were from Sigma-Aldrich Chemie GmbH (Deisenhofen, Germany). Sulfobutylether(V)-
-cyclodextrin (SBE(V)--CD) and sulfobutylether(VII)--cyclodextrin (SBE(VII)--CD) with the
degrees of substitution ca. 4.9 and 6.6, respectively, were obtained from CyDex Pharmaceuticals,
Inc. (Lexexa, KS, USA). Sodium hydroxide solution was from Fisher Scientific (Schwerte,
Germany) and phosphoric acid was from Carl Roth GmbH (Karlsruhe, Germany). (R)-(–)-
chloroquine phosphate was synthesized according to [28]. All buffers and solutions were prepared




The separations were performed using a Beckman Coulter MDQ Instrument (Fullerton, CA, USA)
equipped with an UV detector set at 225 nm. A 40/50.2 cm, 50 m id fused-silica capillary
thermostated at 20°C was used. A new capillary was treated with 1.0 M sodium hydroxide for 20
min, 0.1 M hydrochloric acid for 10 min, water for 10 min and sodium phosphate buffer for 10 min.
Between the injections, the capillary was flushed with 0.1 M sodium hydroxide for 3 min, 0.1 M
phosphoric acid for 2 min, water for 2 min, and the sodium phosphate buffer for 8 min. Samples
were introduced by hydrodynamic injection at 0.5 psi for 6 s. The applied voltage was –25 kV
(reversed polarity, detection at the anode).
The optimized background electrolyte consisted of a 100 mM sodium phosphate buffer prepared by
adjusting 100 mM phosphoric acid to pH 2.5 with 1 M sodium hydroxide solution. CDs were
dissolved in the buffer solution after the adjustment of the pH. The background electrolyte was
replaced after three analyses. Stock solutions of 1.0 mg/mL of racemic chloroquine phosphate and
(R)-(–)-chloroquine were prepared in water. The stock solution of 1.0 mg/mL of the internal
standard carbamazepine was prepared in methanol. The solutions were subsequently diluted with
water to the desired concentrations.
2.3 Method validation
Method validation was conducted according to the ICH guideline Q2(R1) [29] with regard to range,
linearity, limit of detection and quantitation, and precision. Linearity was estimated in the range of
3.0 g/mL to 60 g/mL of racemic chloroquine corresponding to 1.5 g/mL to 30 g/mL for the
individual enantiomers by unweighted linear regression using the least-square method. The limit of
detection and limit of quantitation were based on signal to noise ratio 3:1 and 10:1, respectively.
Precision was determined at a low concentration (3.0 g/mL) and a high concentration (24 g/mL)
of the enantiomers. Intraday precision was calculated from six replicate injections in the same day
while interday precision was based on six injections on three consecutive days.
3. Results and discussion
3.1 Method development
The separation of the chloroquine enantiomers (Figure 1) has been reported using charged CD
derivatives as chiral selectors in acidic background electrolytes [20-23] as well as less frequently
used additives such as human serum albumin [26], colominic acid [25] or arsenyl-L-(+)-tartrate [27].
Due to the commercial availability sulfated -CD and SBE--CD were evaluated. Initial experiments
were conducted using sulfated -CD in concentrations between 5 and 30 mg/mL in a 50 mM
sodium phosphate buffer, pH 2.5. At concentrations of sulfated -CD as low as 5 mg/mL the
compounds could not be detected applying a voltage of 15 - 20 kV under normal polarity. In
contrast, the compounds were detected upon reversing the polarity of the applied voltage.
However, significant peak broadening was observed under these conditions as shown in Figure 2A.
Increasing the concentration of the background electrolyte to 100 mM significantly improved the
peak shape (Figure 2B). Under these conditions the generated current was acceptable (< 100 A).
However, upon injection of a concentrated sample containing 2 mg/mL (R)-(–)-chloroquine and
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about 20 g/mL (S)-(+)-choroquine resulted in a severely distorted peak of the minor enantiomer
which could not be improved increasing the concentration of sulfated -CD or the background
electrolyte or variation of the applied voltage (results not shown).
Subsequently, two batches of SBE--CD varying in the degree of substitution were evaluated.
While no enantioseparation was found in case of the CD with a degree of substitution of 5 (SBE(V)-
-CD), resolution of the chloroquine enantiomers was observed using the CD derivative with an
average substation of 6.6 (SBE(VII)--CD) under reversed polarity of the applied voltage (Figure
2C). It is well known that the degree of substitution of SBE--CD can affect stereoisomer
separations in CE [30-32]. Compared to sulfated -CD, reversal of the enantiomer migration order
was noted. Increasing the concentration of SBE(VII)--CD to 30 mg/mL allowed to raise the
concentration of the chloroquine sample to 3 mg/mL which resulted in an improved LOD of the
enantiomeric impurity. Thus, the optimized conditions employed a 100 mM sodium phosphate
buffer, pH 2.5, containing 30 mg/mL SBE(VII)--CD as the background electrolyte a 50 m id
fused-silica capillary with an effective length of 40 cm at an applied voltage of –25 kV and 20°C.
Under these conditions the current ranged between 80 and 90 A. The total run time was 20 min.
The analytes were detected at 225 nm. Several compounds were evaluated as internal standard
including structurally related compounds such as quinine. However, the compound was not
detected within 30 min under reversed polarity conditions. Finally, carbamazepine was selected as
internal standard which has a migration time of about 6 min.
3.2 Method validation
The optimized method was validated according to the ICH guideline Q2(R1) [29] regarding linearity,
range, LOD, LOQ as well as intraday and interday precision. As pure enantiomers of chloroquine
were not available, racemic drug was used for method validation. A range of 1.5 - 30 g/mL of the
enantiomers was selected which corresponds to a relative concentration of the minor enantiomer of
0.05 % to 1.0 % based on a concentration of the major enantiomer of 3 mg/mL. Carbamazepine at
a concentration of 40 g/mL was used as internal standard to compensate for minor injection errors
and fluctuation of the migration times. The calibration data obtained by unweighted linear
regression are summarized in Table 1. Correlation coefficients of at least 0.997 were observed.
The 95 % confidence intervals of the y-intercepts included zero so that a systematic error can be
excluded. The LOQ was 1.5 g/ml (0.05 %) for both enantiomers and the LOD was 0.6 g/ml (0.02
%). Intraday and interday precision determined at the 0.1 % (3 g/mL) and 0.8 % level (24 g/mL)
was generally below 6 %.
3.3 Sample analysis
The method was applied to the determination of the enantiomeric purity of a synthetic sample of
(R)-(–)-chloroquine prepared according to a published method [28]. The electropherogram of a
sample containing 3.0 mg/mL (R)-(–)-chloroquine and 40 g/mL carbamazepine as internal
standard is shown in Figure 3. 0.24 ± 0.01 % (mean ± SD, n = 3) of the (S)-enantiomer could be
detected corresponding to an enantiomeric purity of 99.52 % of the synthetic sample. Using peak
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normalization the amount of the (S)-enantiomer was 0.35 ± 0.01 % (mean ± SD, n = 3). In addition
to (S)-(+)-chloroquine another impurity (peak X in Figure 3) migrating at about 13 min could be
observed in the laboratory sample. The synthetic precursor 4,7-dichloroquioline has a migration
time of 7.5 min (data not shown) so that the structure of peak X cannot be assigned currently.
Using peak normalization the impurity amounts to about 0.41 ± 0.02 %.
4. Concluding remarks
A stereoselective CE assay was developed and validated for the determination of enantiomeric
purity of synthethic (R)-(–)-chloroquine and (S)-(+)-chloroquine using SBE(VII)--CD as chiral
selector. Interestingly, enantioresolution could not be achieved in the presence of a lower
substituted SBE--CD derivative further illustrating the effect of the substitution of SBE--CD on
chiral separations [30-32].  The optimized method allowed the quantitation of the stereoisomeric
impurity at the 0.05% level. In a laboratory sample of (R)-(–)-chloroquine about 0.24 % of the
enantiomeric impurity was observed. In addition, an unknown impurity at the 0.4 % level could be
detected. Thus, the present CE method may also be suitable for impurity profiling of chloroquine.
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Table 1. Calibration data including intraday and interday precision expressed as RSD values










Correlation coefficient r 0.9985 0.9974
Residual sum of squares 0.0022 0.0038
95% confidence interval of intercept -0.0744 – 0.0170 -0.1023 – 0.0205
Intraday precision (%RSD)
Low level (0.3 g/mL / 0.1%) 3.57 3.30
High level (24 g/mL / 0.8%) 4.75 3.34
Interday precision (%RSD)
Low level (0.3 g/mL / 0.1%) 5.78 3.37
High level (24 g/mL / 0.8%) 4.83 4.26
1) Percent corresponding to a concentration of 3 mg/ml (–)-chloroquine or (+)-chloroquine.
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Figure legends
Figure 1. Structures of (R)-(–)-chloroquine and (S)-(+)-chloroquine as well as carbamazepine
(internal standard).
Figure 2. Electropherograms of the separation of a non-racemic mixture of chloroquine (400
g/mL (R)-(–)-chloroquine ((R)-(–)-CQ) and 200 g/mL (S)-(+)-chloroquine ((S)-(+)-
CQ)) using sulfated -CD (A and B) and SBE(VII)--CD (C) as chiral selector.
Experimental conditions: 50.2/40 cm, 50 m id fused-silica capillary, 20°C, 225 nm, (A)
50 mM sodium phosphate buffer, pH 2.5, 20 mg/mL sulfated -CD, –15 kV, (B) 100
mM sodium phosphate buffer, pH 2.5, 20 mg/mL sulfated -CD, –15 kV and (C) 100
mM sodium phosphate buffer, pH 2.5, 20 mg/mL SBE(VII)--CD, –25 kV.












Figure 3. Electropherogram of a sample containing 3 mg/mL (R)-(–)-chloroquine ((R)-(–)-CQ)
with about 0.3% (S)-(+)-chloroquine ((S)-(+)-CQ) as well as 40 g/mL carbamazepine
(CBZ, IS) using the optimized method. Experimental conditions: 50.2/40 cm, 50 m id
fused-silica capillary, 100 mM sodium phosphate buffer, pH 2.5, 30 mg/mL SBE(VII)--
CD, –25 kV, 20°C, 225 nm.












The discussion is divided into four parts. (1) In this chapter the stereoselective CE assays for
simultaneous determination of charged and neutral impurities in dexamphetamine sulfate are
discussed. A comparison of two cyclodexrtin-mediated capillary zone electrophoresis (CD-
mediated CZE) assays as well as cyclodextrin-modified microemulsion electrokinetic
chromatography (CD-modified MEEKC) assay in both efficiency of the methods and cost analysis
is described. (2) A stereoselective CE assay for the impurity profiling of levodopa is discussed. (3)
A discussion regarding the determination of enantiomeric purity of chloroquine enantiomers as
another example for the applications of stereoselective CE assay is included. (4) Subsequently, the
method development and optimization of all present CE assays are discussed together. A
schematic flow chart showing the strategies for accomplishing stereoisomeric separations of
compounds containing basic and neutral functional groups is developed.
3.1 Stereoselective CE assays for the impurity profiling of dexamphetamine sulfate drug
substances (Manuscript I, II and III)
3.1.1 Profiling of levoamphetamine and related substances in dexamphetamine sulfate by
capillary electrophoresis (Manuscript I)
Dexamphetamine (dextroamphetmamin, 2S-(+)-amphetamine, (S)-1-phenyl-2-propanamine, Fig. 1)
and amphetamine are controlled substances in most European countries and the United States of
America. Dexamphetamine is a central stimulant therapeutically used in the treatment of the
attention deficit hyperactivity disorder of children [56, 57] and narcolepsy [58]. Dexamphetamine
sulfate is described in the monographs of the United State Pharmacopeia 32 (USP 32) [53] and the
British Pharmacopoeia 2009 (BP 2009) [54]. The enantiomeric purity of dexamphetamine sulfate is
characterized by the optical rotation in both pharmacopeias. Besides, the USP also determines the
chromatographic purity limiting individual impurities to 0.1% and the total impurities to 0.5%. No
impurities are specified. As the sensitivity of a simple polarimetric measurement is low, a
stereoselective CE assay was developed in order to obtain the sensitive method as well as the
simultaneous determination of related substances and enantiomeric impurity in dexamphetamine
sulfate.  Dexamphetamine can be prepared from the natural compounds such as 1R,2S-(–)-
norephedrine or 1S,2S-(+)-norpseudoephedrine [59, 60]. Thus, levoamphetamine as well as the
chiral -hydroxy-phenylethylamines was included as potential charged impurities in
dexamphetamine sulfate. The structures of dexamphetamine and potential impurities are shown in
Fig. 1.
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Figure 1. Structures of dexamphetamine, levoamphetamine, 1R,2S-(–)-norephedrine, 1S,2S-(+)-
norpseudoephedrine and the internal standard 1R,2S-(–)-ephedrine.
The CE assay for the enantioseparation of amphetamine has been reported in several studies
employing native cyclodextrins as well as neutral and charged CD derivatives as chiral selectors
[61–64].  Consequently, initial screening tests were performed using a 50 mM phosphate buffer
phosphate buffer, pH 2.5, containing β-CD, 2-hydroxypropyl-β-CD, 2,6-dimethyl-β-CD, 2,3,6-
trimethyl-β-CD, carboxymethyl-β-CD, succinyl-β-CD, sulfated-β-CD and heptakis-(2,3-di-O-acetyl-
6-O-sulfo)-β-CD (HDAS-β-CD) as the background electrolyte. Good resolution (RS > 2) was
obtained with sulfated-β-CD and HDAS-β-CD at concentrations of 1-3 mg/mL. However, only
HDAS-β-CD was selected for method optimization due to better peak shape and the fact that
HDAS-β-CD is a single isomer derivative. Therefore, the batch-to-batch reproducibility will not
affect the performance of the assay. Subsequently, the buffer pH was increased from 2.5 to 3.5
and 6.5 which led to shorter migration time but also poorer peak shape. Thus, the buffer pH at 2.5
was considered to be the optimum. Upon injection of a sample containing dexamphetamine sulfate
at a concentration of 2 mg/mL, peak deformation of the later migrating levoamphetamine was
detected. Increasing the CD concentration from 2 mg/mL to 10 mg/mL as well as the buffer molarity
from 50 mM to 100 mM led to acceptable peak shapes of all analytes with an analysis time of less
than 15 min (Fig. 2A). Peak deformation of the minor peak of levoamphetamine may be caused by
the extensive CD “consumption” by the predominant peak of dexamphetamine. Thus, increasing
the CD concentration can improve the peak shape of levoamphetamine. It was observed that a
further increase in CD concentration up to 20 mg/mL led to a loss of selectivity. Therefore, the
optimized background electrolyte consisted of a 0.1 M phosphate buffer, pH 2.5, containing 10
mg/mL of HDAS-β-CD. The separation was carried out in a 50 m id fused-silica capillary with an
effective length of 46.5 cm at an applied voltage of 25 kV with electric currents of about 90 A and
operated at capillary temperature 20ºC. All compounds were detected at 205 nm. The
electropherogram of a standard solution of 2 g/mL of 1R,2S-(–)-norephedrine and 1S,2S-(+)-
norpseudoephedrine as well as 1.2 g/mL of dexamphetamine and levoamphetamine containing


















Figure 2. Electropherograms of (A) separation of standards (75-144 g/mL), (B) standards at 2
g/mL (1R,2S-(–)-norephedrine and 1S,2S-(+)-norpseudoephedrine) and 1.2 g/mL
(dexamphetamine and levoamphetamine) containing 75 g/mL of ephedrine and (C) commercial
sample of 2.0 mg/mL dexamphetamine sulfate containing 3.8% levoamphetamine. (1) 1S,2S-(+)-
norpseudoephedrine, (2) 1R,2S-(–)-norephedrine, (IS) 1R,2S-(–)-ephedrine, (3) dexamphetamine,
(4) levoamphetamine. Experimental conditions: 0.1 M sodium phosphate buffer, pH 2.5, containing
10 mg/mL HDAS-β-CD; 51/46.5 cm, 50 m id fused-silica capillary; 25 kV; 20ºC.
The optimized method was subsequently validated according to the ICH guideline “Validation of
analytical procedures”, Q2(R1) [52], with regard to linearity, range, limit of detection (LOD), limit of
quantitation (LOQ) as well as intraday and interday precision. Method validation was performed
using the racemic mixture of amphetamine because enantiomerically pure dexamphetamine was
not available. Calibration data performed over a range of 1.2-100 g/mL corresponding to 0.06-5%
based on a concentration of 2 mg/mL dexamphetamine sulfate. Correlation coefficients of at least
0.995 were observed indicating sufficient linearity in the investigated concentration range. The 95%
confidence intervals of the y-intercepts included zero for all analytes, so that a systematic error
could be excluded. The LOQ estimated at a signal-to-noise ratio of 10 was 0.06% (1.2 g/mL) for
all impurities. The LOD estimated at a signal-to-noise ratio of 3 was 0.02% (0.4 g/mL) for 1R,2S-
(–)-norephedrine and 1S,2S-(+)-norpseudoephedrine and 0.03% (0.6 g/mL) for levoamphetamine.
The repeatability of the method was expressed by the relative standard deviation (RSD) values of
the peak area ratios between the analyte and the internal standard. The RSD values of intraday
and interday precision at high and low concentrations were below 7% for all impurities indicating a
sufficient repeatability of the method.
Samples containing 2 mg/mL of commercial dexamphetamine sulfate drug substance and 75
g/mL of the internal standard were subsequently analyzed employing the validated method.
Neither 1R,2S-(–)-norephedrine nor 1S,2S-(+)-norpseudoephedrine could be detected in the
samples. In contrast, the content of levoamphetamine ranged between 2.8 and 4.0% (Fig. 2C,
Table 1). Comparable concentrations of levoamphetamine were determined by peak area
normalization as shown in Table 1. The data indicated that the investigated dexamphetamine
sulfate batches were not synthesized starting from the natural compounds, 1R,2S-(–)-norephedrine
or 1S,2S-(+)-norpseudoephedrine, but may be obtained by other synthetic routes which lead to
racemic amphetamine such as reductive amination starting from 1-phenyl-2-propanone. The




















Table 1. Content of levoamphetamine in commercial samples of dexamphetamine sulfate drugs
substances (means ± SD, n = 3)
















A LOQ of 0.5% was reported for a chiral HPLC assay employing chiral stationary phase [65]. Thus,
the present CE assay with a LOQ of levoamphetamine determination at the 0.06% level was rather
sensitive. Moreover, levoamphetamine as well as related substances can be simultaneously
analyzed. The determination of the enantiomeric purity of dexamphetamine sulfate sample 1 was
also investigated by polarimetry according to the pharmacopeial tests of the USP 32 [53] and the
BP 2009 [54]. A specific rotation of 20D][ = 21.5 ± 0.43° (n=3) was detected. The addition of 2%
and 4% of racemic amphetamine into sample 1 resulted in values of 21.3 ± 0.13° and 21.1 ± 0.17°,
respectively. Therefore, it can be estimated that the dexamphetamine sulfate containing the R-
enantiomer as high as 10% would still pass the tests of specific rotation as described in the
monographs of the USP 32 ( 25D][ = 20 - 23.5°) or the BP 2009 (
20
D][ = 19.5 - 22°). Thus, the CE
assay proved to be superior than using the test of specific rotation, since a dexamphetamine
sample with an enantiomeric excess of as low as 80% would still meet the criteria of the test of the
monographs.
3.1.2 CE assay for simultaneous determination of charged and neutral impurities in
dexamphetamine sulfate using a dual CD system (Manuscript II)
Since none of the charged impurities (1R,2S-(–)-norephedrine and 1S,2S-(+)-norpseudoephedrine)
could be detected in samples of commercial dexamphetamine sulfate drug substances, it was
hypothesized that dexamphetamine was synthesized starting from phenylacetone (1-phenyl-2-
propanone, benzyl methyl ketone) via Leuckart reaction or by reduction of phenylacetone oxime
[66, 67] followed by fractional crystallization with L-(+)-tartaric acid [68]. Thus, charged as well as
neutral starting materials or by-products as well as the enantiomer levoamphetamine may be
present as related substances in dexamphetamine sulfate. Therefore, the aim of the study was the
development and validation of a stereoselective CE assay for the determination of
dexamphetamine allowing the simultaneous analysis of charged as well as neutral impurities. The
structures of investigated compounds are shown in Fig. 3.
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Figure 3. Structures of dexamphetamine, charged and neutral potential impurities as well as an
internal standard, 1R,2S-(–)-ephedrine.
The enantioseparations of phenylalkylamines such as amphetamine, methamphetamine and
ephedrine have been studied employing negatively charged CD derivatives including randomly
sulfated CDs [64, 69–71] and sulfobutylether-CDs [69, 72]. Thus, various negatively charged CDs,
e.g., sulfated -CD, sulfated -CD, sulfated -CD, heptakis-(2,3-di-O-acetyl-6-O-sulfo)--CD,
carboxymethyl--CD, carboxymethyl--CD, sulfopropyl--CD, sulfopropyl--CD and SBE(V)--CD
dissolved in 50 mM phosphate buffer, pH 2.5,  were investigated for their ability to separate the
enantiomers of amphetamine and the neutral impurities phenylacetone and phenylacetone oxime.
None of neutral impurities could be detected by any initial screening tests employing the normal
polarity of the applied voltage. Therefore, reversed polarity allowing higher concentrations of the
CDs that were intended to be used as a chiral selector as well as a carrier for neutral impurities
was considered for the method development. The baseline separation of amphetamine
enantiomers, phenylacetone and phenylacetone oxime was observed at reversed polarity of the
applied voltage and a BGE containing sulfated -CD or SBE(V)--CD (DS 4.9). Sulfated -CD
displayed high resolution of amphetamine enantiomers at a concentration of 20 mg/mL (Rs > 3) but
none of neutral analytes could be detected within 60 min. Increasing the concentration of sulfated
-CD from 20 mg/mL to 40 mg/mL the neutral analytes migrated at about 45 min but the peaks
were rather broad. In contrast, a high concentration of 80 mg/mL of SBE(V)--CD was necessary
for baseline resolution of the amphetamine enantiomers (Fig. 4) but phenylacetone and its oxime
migrated before amphetamine. At concentrations of 70 mg/mL of SBE(V)--CD or below broad
peaks and/or peak splitting was observed (see also Fig. 4). It was observed that an increase in the
concentration of SBE(V)--CD from 20 mg/mL  to 80 mg/mL resulted in baseline separations and
acceptable peak shapes of the amphetamine enantiomers as well as neutral impurities and a
shorter migration time. Subsequently, a dual CD system comprising sulfated -CD for the effective
resolution of amphetamine enantiomers as shown in Fig. 4 and SBE(V)--CD for the separation of
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Figure 4. Effects of CD concentrations and compositions of the BGE to the separation of the
amphetamine enantiomers (1 mg/mL) under otherwise identical conditions.
A concentration of 5 mg/mL of dexamphetamine sulfate was necessary in order to enable the
determination of impurities at the 0.1% level. Thus, the concentration of sulfated -CD in the
presence of 80 mg/mL of SBE(V)--CD was varied between 10 and 30 mg/mL in order to achieve a
baseline separation of all analytes. The background electrolyte composed of 25 mg/mL sulfated -
CD and 80 mg/mL of SBE(V)--CD resulted in an acceptable peak shape of all analytes (Fig. 5A).
During the method development it was observed that phenylacetone oxime separated into two
peaks when a concentration of SBE(V)--CD above 50 mg/mL was employed. Oximes can exist in
two stereoisomers with E or Z configuration which can be distinguished, among others, by NMR
spectroscopy. Subsequently, the phenylacetone oxime sample was analyzed by NMR
spectroscopy and the present CE assay. The signals obtained from 1H-NMR spectroscopy as well
as the peak area ratio of 1:2.9 of the two peaks obtained from the CE assay were comparable with
literature data. Thus, the two peaks can be assigned as phenylacetone Z-oxime and phenylacetone
E-oxime, respectively (Fig. 5A). The partial overlap of the oximes could be overcome by increasing
the buffer pH from 2.5 to 3.0 (Fig. 5B). It was observed that an increase in the buffer pH led to a
long migration time as well.
Furthermore, the effective length of the capillary was shortened from 45 to 35 cm in order to reduce
the analysis time. The applied voltage was increased in order to obtain a faster analysis. However,
increasing the applied voltage from –10 kV to –15 kV resulted in currents above 100 A which led
to a poor peak resolution due to Joule heating. Thus, the voltage was reduced to –10 kV, which





+ 10 mg/mL sulfated β-CD
80 mg/mL SBE(V)-β-CD
+ 20 mg/mL sulfated β-CD
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In summary, the optimized background electrolyte consisted of a 50 mM phosphate buffer, pH 3.0,
containing 80 mg/mL of SBE(V)--CD and 25 mg/mL of sulfated -CD. The separation was carried
out in a 50 m id fused-silica capillary with an effective length of 35 cm (a total length of 40.2 cm) at
an applied voltage of –10 kV and operated at capillary temperature 20ºC. Detection was carried out
at 200 nm. The separation of the enantiomers of amphetamine, the positively charged potential
impurities 1S,2S-(+)-norpseudoephedrine and 1R,2S-(–)-norephedrine, the neutral potential
impurities phenylacetone and phenylacetone oxime as well as 1R,2S-(–)-ephedrine (selected as
internal standard) employing the optimized conditions is shown in Fig. 5B.
Figure 5. Effect of the pH of the background electrolyte on analyte separation of a sample of 5
mg/mL dexamphetamine sulfate containing about 3 % levoamphetamine and spiked with 1.0% (50
g/mL) of the impurities as well as 70 g/mL ephedrine (IS). Background electrolyte: 50 mM
sodium phosphate buffer (A) pH 2.5, (B) pH 3.0, containing 80 mg/mL SBE(V)--CD and 25 mg/mL
sulfated -CD. Experimental conditions: 40.2/35 cm, 50 m id fused-silica capillary, –10 kV, 20°C.
1, phenylacetone Z-oxime; 2, phenylacetone E-oxime; 3, phenylacetone; 4, dexamphetamine; 5,
levoamphetamine; 6, 1S,2S-(+)-norpseudoephedrine; 7, 1R,2S-(–)-norephedrine; 8, 1R,2S-(–)-
ephedrine.
Commercial sulfobutylether -CD exists in qualities with different substitution patterns, which can
affect the stereoisomer separations [69, 73]. Thus, CDs with different degree of substitution (DS), i.
e. SBE(IV)--CD (DS 4) and SBE(VII)--CD (DS 7), were investigated in comparison to SBE(V)--
CD. Sample containing 5 mg/mL of dexamphetamine sulfate as well as 1% of the potential
impurities was analyzed. The separations obtained from the three sulfobutylether -CDs at a
concentration of 80 mg/mL and 20 mg/mL of sulfated -CD under otherwise identical conditions
were summarized in Fig. 6. The DS affected peak shape and peak resolution, especially the
separation of the amphetamine enantiomers. Peak distortion was observed for SBE(IV)--CD (Fig.
6A), whereas peak resolution between the amphetamine enantiomers was decreased using
SBE(VII)--CD as chiral selector (Fig. 6B). Good resolution of all analytes was obtained for
SBE(V)--CD, but peak splitting of levoamphetamine which migrated after dexamphetamine was
observed as well (Fig. 6C). Peak splitting could be overcome by increasing the concentration of
sulfated -CD to 25 mg/mL (Fig. 6D). It was noted that a further increase in a concentration of
sulfated -CD to 30 mg/mL resulted in a partial overlap of the peaks of phenylacetone and
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dexamphetamine. Minor changes of the concentrations of both CDs in the range of ±1-2 mg/mL
within the optimized conditions did not show significant effects on peak resolution or peak shape of
all analytes. The concentration of the individual CDs and the composition of the BGE affect peak
shape and resolution (see also Fig. 6). Therefore, the system can be optimized by adjustments of
the concentration of one or both of the employed CDs as well as the buffer pH in order to achieve
the sufficient peak resolution and peak shape for quantitation of all impurities. Moreover, a system
suitability test using dexamphetamine and levoamphetamine with strongly different concentrations,
e. g., 5 mg/mL of dexamphetamine and 3-5% of levoamphetamine, as a critical pair should be
employed when sulfobutylether -CDs with a DS different from 5 is utilized.
Figure 6. Effect of the DS of SBE--CD on peak shape and peak resolution. (A) SBE(IV)--CD, (B)
SBE(VII)--CD, (C) SBE(V)--CD. A sample of 5 mg/mL dexamphetamine sulfate containing about
3 % levoamphetamine and spiked with 1% (50 g/mL) of the impurities as well as 70 g/mL
ephedrine. Background electrolyte: 50 mM phosphate buffer, pH 3.0, containing (A) 80 mg/mL
SBE(IV)--CD and 20 mg/mL sulfated -CD, (B) 80 mg/mL SBE(VII)--CD and 20 mg/mL sulfated
-CD, (C) 80 mg/mL SBE(V)--CD and 20 mg/mL sulfated -CD, and (D) 80 mg/mL SBE(V)--CD
and 25 mg/mL sulfated -CD. Other experimental conditions and peak assignment see Fig. 5.
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The optimized method was subsequently validated according to the ICH guideline “Validation of
analytical procedures”, Q2(R1) [52], with regard to linearity, range, limit of detection (LOD), limit of
quantitation (LOQ) as well as intraday and interday precision. As before, method validation was
performed using the racemic amphetamine. Levoamphetamine was validated over the range of
0.05-5% (2.5-250 g/mL) based on the concentration of 5 mg/mL of dexamphetamine sulfate. All
other impurities were validated over the range of 0.05-1% (2.5-50 g/mL). 1R,2S-(–)-ephedrine
was used as internal standard at a concentration of 70 g/mL. The LOQ estimated at a signal-to-
noise ratio of 10 was 0.05% (2.5 g/mL) for all potential impurities. The LOD estimated at a signal-
to-noise ratio of 3 was 0.02% (1 g/mL) for the charged impurities and 0.01% (0.5 g/mL) for
neutral impurities. Correlation coefficients of at least 0.993 were observed indicating sufficient
linearity in the investigated concentration range. The RSD values of intraday and interday precision
at high and low concentrations were below 8% for all impurities indicating a sufficient repeatability
of the method.
The validated method was subsequently applied for the analysis of commercial samples of
dexamphetamine sulfate. Samples containing 5 mg/mL of dexamphetamine drug substance and 70
g/mL of ephedrine were analyzed. In accordance with earlier results (Manuscript I), neither
1R,2S-(–)-norephedrine nor 1S,2S-(+)-norpseudoephedrine could be detected in any sample. In
contrast, levoamphetamine was present at concentrations between 3.2 and 3.7%, which are in
accordance with the earlier study as well. Interestingly, peaks corresponding to phenylacetone and
isomers of phenylacetone oxime were observed at a concentration of the LOD or below. Regarding
the disregard limit of the European Pharmacopoeia [55] the neutral impurity with quantities below
the LOQ would not be considered necessary. However, the presence of phenylacetone and the
oximes demonstrate that the investigated batches of commercial dexamphetamine sulfate were
synthesized starting from phenylacetone via the oxime and subsequently resolved the enantiomers
by fractional crystallization. The analysis of commercial dexamphetamine sulfate samples is
summarized in Table 2. The quantities of levoamphetamine obtained from peak area normalization
are generally higher but are in general agreement with the values obtained from the calibration
data.
Table 2. Impurity profile of commercial dexamphetamine sulfate samples (mean ± SD, n = 3)
Compound Sample 1 Sample 2 Sample 3 Sample 4
Phenylacetone Z-oxime NDa) LODb) LOD LOD
Phenylacetone E-oxime LOD LOD LOD LOD
Phenylacetone LOD LOD LOD LOD
1S,2S-(+)-Norpseudoephedrine ND ND ND ND
1R,2S-(–)-Norephedrine ND ND ND ND
Levoamphetamine (calibration) 3.23 ± 0.02 3.70 ± 0.15 3.38 ± 0.09 3.36 ± 0.06
Levoamphetamine (normalization) 3.88 ± 0.06 4.25 ± 0.07 4.01 ± 0.11 3.47 ± 0.04
a) ND: not detectable
b) LOD: detected at the LOD level
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3.1.3 Impurity profiling of dexamphetamine sulfate by cyclodextrin-modified microemulsion
electrokinetic chromatography (Manuscript III)
Microemulsion electrokinetic chromatography (MEEKC) has proven to be a powerful technique for
the analysis of charged and uncharged compounds including stereoisomer analysis. However,
since the application of MEEKC to the simulteneous determination of achiral impurities of drugs
and the analysis of the enantiomeric purity has not been reported to date, the present study was
conducted in order to evaluate cyclodextrin-modified MEEKC for the simultaneous determination of
stereoisomeric purity as well as impurity profiling of dexamphetamine sulfate. The drug and its
impurities (Fig. 7) comprise charged and uncharged analytes, chiral and achiral analytes or a piar
of enantiomers as well as a pair of E- and Z-geometrical isomers. Dexamphetamine and
levoamphetamine represent the pair of enantiomers as well as charged compounds.
Phenylacetone is uncharged and achiral compound. Phenylacetone oxime represents uncharged
compound as well as the pair of geometric isomers. Both 1S,2S-(+)-norpseudoephedrine and
1R,2S-(–)-norephedrine represent charged and chiral compounds.
Figure 7. Structures of dexamphetamine and potential impurities as well as the internal standard
carbamazepine.
Micellar electrokinetic chromatography (MEKC) was initially evaluated using background
electrolytes with pH values of 9.5 and 3.0 containing 3.5% w/w SDS and 5-8% of organic solvent
such as 1-butanol, 2-propanol, acetonitrile or methanol. None of the investigated conditions
resulted in acceptable peak shape, baseline noise or (achiral) separation of all analytes (see also
Fig. 8). However, as the initial test employing 2-propanol modified MEKC at low pH with reversed
polarity of the applied voltage showed a promising baseline separation of amphetamine and neutral
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Figure 8. The electropherograms of sample containing 1 mg/mL of racemic amphetamine, 0.2
mg/mL of phenylacetone oxime and 0.1 mg/mL of phenylacetone. The BGE consisted of (A) 5 mM
sodium borate buffer, pH 9.5 (normal polarity); (B) 50 mM sodium phosphate buffer, pH 3.0
(reversed polarity), containing 3.5% w/w SDS and 8% w/w 2-propanol. For peak assignments, see
Fig. 7.
Initially, tested MEEKC conditions were modified starting from a suppressed electroosmosis CD-
modified MEEKC assay for the enantioseparation of phenylalanine derivatives published by Brost
and Holzgrabe [74]. Thus, a microemulsion containing a 50 mM phosphate buffer, pH 3.0, ethyl
acetate, SDS, 1-butanol, 2-propanol and sulfated -CD was evaluated for the simultaneous
determination of dexamphetamine and the R-enantiomer as well as related substances. A solution
of 2 mg/mL dexamphetamine sulfate containing about 3% of levoamphetamine and 1% of the
impurities as well as 1R,2S-(–)-ephedrine as internal standard was used for method development.
Fig. 9A shows the separation of the analytes using a microemulsion composed of 1.4% w/w SDS,
1.0% w/w ethyl acetate, 4.0% w/w 1-butanol, 2.8% w/w 2-propanol, 90.8% w/w 50 mM phosphate
buffer, pH 3.0, containing 4.0% w/w sulfated -CD under reversed polarity of the applied voltage.
Although the enantiomers of amphetamine were well separated, the intended internal standard
1R,2S-(–)-ephedrine comigrated with 1S,2S-(+)-norpseudoephedrine and phenylacetone Z-oxime
was not completely separated from dexamphetamine. It was noted that the separation of all
analytes could be resolved by variations of the composition of the microemulsion and the CD
concentration. Thus, the effects of each composition in the background electrolyte on the
separation were investigated and discussed as follows.
- SDS (the surfactant): Increasing the concentration of SDS to 2.0% w/w essentially led to
a loss of the enantioseparation of amphetamine and a partial overlap of 1R,2S-(–)-ephedrine,
1S,2S-(+)-norpseudoephedrine and phenylacetone E-oxime. Thus, the concentration of 1.5% w/w
SDS was selected for further method development.
- Ethyl acetate (the oil core): It was observed that the content of ethyl acetate used as an
oil core had a significant effect to the separation of all analytes, especially for the separation of the










amphetamine enantiomers. Decreasing the content of ethyl acetate to 0.5% w/w with a reduction of
the co-surfactant 1-butanol to 3.0% w/w and the organic modifier 2-propanol to 2.0% w/w resulted
in a comigration of the amphetamine enantiomers, although all other analytes were sufficiently
separated (Fig. 9B). Increasing the content of ethyl acetate to 1.0% w/w resulted in an
improvement of the enantioseparation, but the partial overlap of 1S,2S-(+)-norpseudoephedrine
and 1R,2S-(–)-norephedrine was observed as well (Fig. 9C). Because of the baseline separation of
related compounds, the content of ethyl acetate at 0.5% w/w was selected for further optimization
of the CD concentration in order to improve the baseline separation of dexamphetamine and
levoamphetamine.
Figure 9. Effect of the composition of the microemulsion on analyte separation. Background
electrolyte: (A) 1.4% w/w SDS, 1.0% w/w ethyl acetate, 4.0% w/w 1-butanol, 2.8% w/w 2-propanol,
90.8% w/w phosphate buffer, pH 3.0, containing 4.0% w/w sulfated -CD; (B) 1.5% w/w SDS,
0.5% w/w ethyl acetate, 3.0% w/w 1-butanol, 2.0% w/w 2-propanol, 93.0% w/w phosphate buffer,
pH 3.0, containing 4.0% w/w sulfated -CD; (C) 1.5% w/w SDS, 1.0% w/w ethyl acetate, 3.0% w/w
1-butanol, 2.0% w/w 2-propanol, 92.5% w/w phosphate buffer, pH 3.0, containing 4.0% w/w
sulfated -CD. Other experimental conditions: 50.2/40 cm, 50 m id fused-silica capillary, -15 kV,
20°C; sample: 2 mg/mL dexamphetamine sulfate containing about 3% levoamphetamine and 1% of
the other impurities as well as 70 g/mL 1R,2S-(–)-ephedrine. For peak assignment, see Fig. 7.
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- Sulfated -CD (the chiral selector): The CD was intended as a chiral selector for the
amphetamine enantiomers. Subsequently, the variation of the CD concentration from 4% w/w to
8% w/w was investigated (see also Fig. 10). As partial overlap of phenylacetone E-oxime and
1R,2S-(–)-ephedrine was observed when a CD concentration above 5% w/w was used, 1R,2S-(–)-
ephedrine was not further employed. Instead, carbamazepine was selected as an internal standard
due to the peak shape and short migration time. Baseline separation of all analytes could be
achieved by increasing the concentration of sulfated -CD to 5.5% w/w (Fig. 8). A further increase
of sulfated -CD above 6% w/w resulted in unstable baseline as well as partial overlap of
phenylacetone Z-oxime and dexamphetamine. Thus, sulfated -CD at a concentration of 5.5% w/w
was used for further optimization.
Figure 10. Effects of CD concentration on analyte separation. Background electrolyte: 1.5% w/w
SDS, 0.5% w/w ethyl acetate, 3.0% w/w 1-butanol, 2.0% w/w 2-propanol, 93.0% w/w phosphate
buffer, pH 3.0, containing concentrations between 5.0 and 7.5% w/w of sulfated -CD. Sample: 2
mg/mL dexamphetamine sulfate containing about 3% levoamphetamine and 1% of the other
impurities as well as 50 g/mL carbamazepine. For other experimental conditions, see Fig. 9. For
peak assignment, see Fig. 7.
Discussion 73
- 1-Butanol and 2-propanol (co-surfactant and organic modifier): It was observed that an
increase in the content of 1-butanol or 2-propanol in the BGE resulted in an improvement of the
enantiosepartion of amphetamine. Therefore, the final fine tuning of the microemulsion was
performed by variation of the contents of 1-butanol between 3.0 and 4.0% w/w and of 2-propanol in
the range between 2.0 and 3.0% w/w. The best separation of all analytes was achieved using 3.5%
w/w 1-butanol and 2.5% w/w 2-propanol, which allowed the separation of a sample of 3 mg/mL
dexamphetamine sulfate. A further increase in 1-butanol and 2-propanol above 4% w/w and 3%
w/w, respectively, may lead to a disruption of microemulsion system, since none of impurities could
be detected and an unstable baseline was observed as well.
- Buffer concentration and buffer pH: Furthermore, the buffer concentration was varied
between 20 and 100 mM. Reduction of the buffer concentration to 20 mM resulted in peak
broadening, while an increase in the buffer pH to 100 mM led to currents above 100 A.
Decreasing the buffer pH to 2.0 led to a depletion of the peak height of phenylacetone E-oxime,
whereas the other compounds were not affected.
The final optimized method employed the background electrolyte containing 1.5% w/w SDS, 0.5%
w/w ethyl acetate, 3.5% w/w 1-butanol, 2.5% w/w 2-propanol and 92% w/w 50 mM phosphate
buffer, pH 3.0, containing 5.5% w/w sulfated -CD. The separation was carried out in a 50 m id
fused-silica capillary with an effective length of 40 cm at an applied voltage of –14 kV (currents
between 73 and 78 A), operated at 20°C. The detection wavelength was 200 nm. The separation
of a sample of 3 mg/mL dexamphetamine sulfate containing about 3% levoamphetamine, 1% of the
impurities and 50 g/mL of carbamazepine as internal standard is shown in Fig. 11A.
During method development, it was observed that preparation of the microemulsion affected the
separation between dexamphetamine and levoamphetamine as well as between phenylacetone E-
oxime and 1S,2S-(+)-norpseudoephedrine depending on the addition of sulfated -CD either before
or after the preparation of the microemulsion. No apparent explanation can be concluded for this
phenomenon. Good resolution between the amphetamine enantiomers as well as phenylacetone
E-oxime and 1S,2S-(+)-norpseudoephedrine was achieved using the background electrolyte
prepared by adding sulfated -CD to the phosphate buffer prior to the preparation of the
microemulsion (see also Fig. 11A). Thus, this background electrolyte was used for the validation
and sample analysis. A slightly decrease in the resolution was observed employing a background
electrolyte prepared by adding sulfated -CD to the phosphate buffer after the preparation of the
microemulsion (Fig. 11B).
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Figure 11. Effect of preparation of the background electrolyte on ananlyte separation. (A) Addition
of sulfated -CD to the phosphate buffer prior to the preparation of the microemulsion by sonication
and (B) addition of sulfated -CD to the phosphate buffer after preparation of the microemulsion.
Experimental conditions: 50.2/40 cm, 50 m id fused-silica capillary, –15 kV, 20°C; background
electrolyte: 1.5% w/w SDS, 0.5% w/w ethyl acetate, 3.5% w/w 1-butanol, 2.5% w/w 2-propanol and
92% w/w 50 mM phosphate buffer, pH 3.0, containing 5.5% w/w sulfated -CD; sample: 3 mg/mL
dexamphetamine sulfate containing about 3% levoamphetamine and 30 g/mL (1%) of the other
impurities as well as 50 g/mL carbamazepine as internal standard (IS). For peak assignment, see
Fig. 7.
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The optimized method was subsequently validated according to the ICH guideline “Validation of
analytical procedures”, Q2(R1). Method validation was performed using racemic amphetamine.
Levoamphetamine was validated over the range of 3-150 g/mL corresponding to 0.1-5% based on
the concentration of 3 mg/mL of dexamphetamine sulfate. All other impurities were validated over
the range of 3-30 g/mL (0.1-1%) except for phenylacetone Z-oxime which was calibrated between
15 and 30 g/mL (0.5-1%). Carbamazepine was used as internal standard at a concentration of 50
g/mL. The LOQ estimated at a signal-to-noise ratio of 10 was 0.1% (3 g/mL) for all potential
compounds except for phenylacetone Z-oxime with a LOQ of 0.5% (15 g/mL). The LOD estimated
at a signal-to-noise ratio of 3 was 0.05% (1.5 g/mL) for the impurities, while a LOD for the Z-oxime
was 0.2% (6 g/mL). Correlation coefficients of at least 0.994 were observed indicating sufficient
linearity in the investigated concentration range. The repeatability of the method was expressed by
the relative standard deviation (RSD) values of the peak area ratios between the analyte and the
internal standard. The RSD values of intraday and interday precision at high and low
concentrations were below 8.2% for all impurities.
Four commercial samples of dexamphetamine sulfate were subsequently analyzed employing the
validated method. Levoamphetamine was detected in all dexamphetamine samples at
concentrations between 3.22 ± 0.10 and 3.82 ± 0.07% (n=3). Other potential impurities could not
be detected because the employed CD-modified MEEKC method is less sensitive than the method
employing a dual CD system.
3.1.4 Concluding remarks (Manuscript I, II and III)
Three stereoselective CE assays were developed and validated for the simultaneous determination
of dexamphetamine and levoamphetamine as well as related substances. A CE assay employing
HDAS--CD as a chiral selector was initially developed. The assay was subsequently applied for
the determination of the stereoisomeric purity of commercial dexamphetamine samples. As none of
the charged impurities 1S,2S-(+)-norpseudoephedrine and 1R,2S-(–)-norephedrine could be
detected, a stereoselective CE assay employing a dual CD system comprising of SBE(V)--CD and
sulfated -CD was subsequently developed. The CE assay employing the dual CD system
provides a lower LOQ value than the method using a single CD system, moreover the
amphetamine enantiomers as well as potential charged, 1S,2S-(+)-norpseudoephedrine and
1R,2S-(–)-norephedrine and neutral impurities, phenylacetone and phenylacetone oxime, can be
detected simultaneously. Subsequently, a CE assay employing CD-modified MEEKC was
developed as an alternative method to the use of the expensive CDs HDAS--CD and
sulfobutylether -CD. The optimized CD-modified MEEKC method allowed the simultaneous
determination of the amphetamine enantiomers as well as potential charged and uncharged related
substances. Among those developed CE assays, the dual CD system seems to be the most
suitable analytical method for the determination of dexamphetamine and related substances. Both
charged and uncharged compounds can be analyzed simultaneously and the impurities can be
quantified at a lower LOQ value compared to the CE assays employing either a single CD system
or CD-modified MEEKC technique. A disadvantage is the fact that SBE(V)--CD is rather
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expensive. Finally, three different CE assays used for the simultaneous determination of the
enantiomeric purity of dexamphetamine sulfate and its potential impurities are summarized and
compared in Table 3.
Table 3. Comparison of stereoselective CE assays for the simultaneous determination of the
enantiomeric purity of dexamphetamine sulfate and related substances.
CE assays Single CD system Dual CD system CD-modified MEEKC
Optimized method:
Chiral selector HDAS--CD SBE(V)--CD and
sulfated -CD
sulfated -CD







Range 0.06 – 5.0% 0.05 – 1.0%
0.05 – 5.0% (R-Amp)
0.1 – 1.0%,
0.5 – 1.0% (Z-oxime)
0.1 – 5.0% (R-Amp)











Precision (%RSD) <7% <8% <8.2%
Sample analysis 2 mg/mL 5 mg/mL 3 mg/mL
Internal standard 1R,2S-(–)-ephedrine 1R,2S-(–)-ephedrine carbamazepine


















Not applicable Not applicable SDS; 166 $ /kg
EtOAc; 81.82 $ /L
1-BuOH; 61.3 $ /0.5L
2-PrOH; 39.76 $ /0.5L
SDS; sodium dodecyl sulfate, EtOAc; ethyl acetate, 1-BuOH; 1-butanol, 2-PrOH; 2-propanol
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3.2 A stereoselective CE assay for the simultaneous determination of related substances
and the enantiomeric purity of levodopa: comparision with the pharmacopeial polarimetric
and HPLC methods (Manuscript IV)
Levodopa is the (S)-enantiomer of 3,4-dihydroxyphenylalanine (Fig. 12) that is used in the
treatement of Parkinson’s disease. Levodopa and tests for the the determination of related
substances and of the enantiomeric purity are described in the European Pharmacopoeia [55] and
the United States Pharmacopeia [53]. The related substances specified by the pharmacopeias
include L-tyrosine (Tyr), 3-methoxy-L-tyrosine (3-OMe-Tyr), and racemic 6-hydroxy-D,L-dopa (6-
OH-DOPA) as shown in Fig 12. As no assay allowing the simultaneous determination of
enantiomeric purity of levodopa as well as related substances has been published, a
stereoselective CE assay was developed.
Figure 12. Structures of levodopa, D-DOPA and related substances as well as the internal
standard L-Phe.
Initial screening tests employed a sodium phosphate buffer containing 2 mg/mL sulfated -CD with
normal polarity of the applied voltage. The buffer molarity between 20 mM and 200 mM, pH
between 2.0 and 3.0, was evaluated in a capillary with an effective length of 40 cm and an applied
voltage of 20 kV. Sharp peaks and short migration times were observed lowering the buffer pH
from 3.0 to 2.0. With regard to buffer molarity, a 0.12 M phosphate buffer provided a good
compromise between peak shape and electric current (below 100 A). However, under these
conditions Tyr comigrated with levodopa. Subsequently, the CD concentration was varied between
2 and 8 mg/mL in order to achieve baseline separation and acceptable peak shape of all analytes
(see also Fig. 13). At a concentration of 8 mg/mL of sulfated -CD good resolutions as well as
sharp peaks were achieved for all compounds. In addition, the stereoisomers of 6-OH-DOPA were
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Figure 13. Effect of the concentration of sulfated -CD on the separation of levodopa and its
specified impurities. Experimental conditions: 0.12 M phosphate buffer, pH 2.0, containing (A) 2
mg/mL sulfated -CD, (B) 4 mg/mL sulfated -CD, (C) 6 mg/mL sulfated -CD, and (D) 8 mg/mL
sulfated -CD; 50.2/40 cm fused-silica capillary, 20 kV, 18°C. Sample concentration: 2 mg/mL
levodopa containing 1.0% of 3-OMe-Tyr and D-DOPA, 0.5% of Tyr, and 0.1% of 6-OH-DOPA.
Interestingly, when the phosphate buffer was prepared from orthophosphoric acid and sodium
hydroxide, the buffer molarity and sulfated -CD could be reduced to 0.1 M and 6 mg/mL,
respectively, with comparable resolution as shown in Fig. 13D. Increasing the applied voltage to 25
kV led to the currents above 100 A, moreover the partial overlap between Tyr and D-DOPA was
observed. Thus, the optimized conditions employed a 0.1 M phosphate buffer, pH 2.0, prepared
from orthophosphoric acid and sodium hydroxide solution containing 6 mg/mL of sulfated -CD as
background electrolyte, a 50 m id fused-silica capillary with an effective length of 35 cm (total
length 45.2 cm), an applied voltage of +20 kV and 18°C capillary temperature. Due to the fact that
a randomly substituted sulfated -CD as commercially available and low price CD derivative was
selected in the present study, two batches of the CDs from other suppliers were tested with regard
to the reproducibility of the separation of the analytes. Clearly, the different samples of sulfated -
CD affected the separation, especially the critical resolution between levodopa and Tyr. However,
an increase in the CD concentration can improve the resolution of the analytes.
The optimized method was subsequently validated according to the ICH guideline “Validation of
analytical procedures”, Q2(R1). All impurities were validated over the range of 2-20 g/mL
corresponding to 0.1-1% based on the concentration of 2 mg/mL of levodopa drug substance.














































































at a signal-to-noise ratio of 10 was 0.1% (2 g/mL) for all impurities. The LOD estimated at a
signal-to-noise ratio of 3 was between 0.03% (0.6 g/mL) and 0.04% (0.8 g/mL). Correlation
coefficients of at least 0.990 were observed indicating sufficient linearity in the investigated
concentration range. The RSD values of intraday and interday precision at high and low
concentrations were below 10% for all impurities.
The method was subsequently applied to determine the related substances as well as D-DOPA in
samples of levodopa including the chemical reference substance of the European Pharmacopoeia.
Neither 6-OH-DOPA nor 3-OMe-Tyr could be detected. In contrast, Tyr could be detected in all
samples at a concentration below the LOQ, which is in accordance with the data reported by
Schieffer G. W. [75]. An amount of D-DOPA of 0.15 ± 0.01% was obtained from the reference
substance of the European Pharmacopoeia, which is in accordance with the requirement of the
European Pharmacopoeia for enantiomeric purity test of levodapa.
The related substances of levodopa are determined by comparable HPLC assays by the European
Pharmacopoeia and the United States Pharmacopeia. The enantiomeric purity of levodopa is
determined by optical rotation by the United States Pharmacopeia based on the increased optical
rotation of levodopa in the presence of methenamine while the European Pharmacopoeia uses
enantioselective HPLC based on a chiral ligand exchange method published by Doležalová and
Tkaczyková [76]. A LOD of D-DOPA of 0.04% was reported, which is more sensitive than the
measurement of the optical rotation of the sample. However, the negative peaks are observed
between the peak of levodopa and D-DOPA, which may make reproducible integration difficult. The
electropherogram of a sample containing 2 mg/mL levodopa and 0.5 % of the impurities using the
present CE assay and a chromatogram of HPLC assay are shown in Fig. 14. Furthermore, a
comparison made for the official analytical methods and the present CE assay regarding the
determination of the enantiomeric purity of levodopa and the related substances is shown in
Table 4. The simultaneous determination of enantiomeric purity and related substances of
levodopa as specified by the European Pharmacopoeia can be achieved only by employing the
present CE assay, which also provides a sufficient sensitivity with a LOQ of 0.1% for all impurities
as well as short analysis time for the determination of all analytes. Moreover, since the resolution of
all analytes as shown in Fig. 14B is rather, a high increase in a sample amount of major compound
along with or without an increase in a CD concentration in order to obtain a LOQ value below the
0.1% level may be possible.
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Figure 14. (A) Chromatogram of levodopa containg 0.5% of D-DOPA (reproduced from Ref. [76])
and (B) Electropherogarm of 2 mg/mL levodopa containing 0.5% of D-DOPA as well as related


















Table 4. Official analytical methods and the stereoselctive CE assay used for the determination of
the enantiomeric purity and related compounds of levodopa drug substance.
USP 32a) Ph. Eurb) The present CE
Enantiomeric purity:















pH 4.0, and methanol
Flow rate;1.0 mL/min
Capillary; 45.2/35 cm,
50 m id  fused-silica
capillary, 20 kV, 18°C




Analysis time at least 3 hours 20 min 35 min
LOD Not available 0.04%c) 0.04%
Related substances:
Method HPLC HPLC (ligand exchange) CD-mediated CZE
Experimental
conditions
Column; 4.6 mm × 25
cm, spherical octadecyl
silane
Mobile phase; a mixture




Flow rate; 1 mL/min




Gradient elution; (A) 0.1
M phosphate buffer, pH
3.0, (B) methanol and
0.1 M phosphate buffer,
pH 3.0 (18:85 V/V)
Flow rate; 1 mL/min
Capillary; 45.2/35 cm,
50 m id fused-silica
capillary, 20 kV, 18°C




Analysis time Not available 6 min for levodopa 35 min






Not possible Not possible Possible. All compounds
can be detected in one
injection with total
analysis time of 35 min
a) The United State Pharmacopeia (32th Edition) [53]
b) The European Pharmacopoeia (7th Edition) [55]
c) reported by Doležalová and Tkaczyková [76]
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3.3 Development and validation of a capillary electrophoresis assay for the determination of
the stereoisomeric purity of chloroquine enantiomers (Manuscript V)
Chloroquine is commercially available as racemate used as chemotherapeutic drug for the
prophylaxis and the treatment of malaria. Differences in the antimalarial activity and toxicity of the
enantiomers have been reported in vivo. Moreover, the enantiomers appear to be less embryotoxic
compared to the racemate. Due to these data the further study of stereoselective pharmacology
and pharmacodynamics of the drug is necessary. Thus, an assay for the determination of the
enantiomeric purity is important. The separation of the chloroquine enantiomers has been reported
using charged CD derivatives as chiral selectors in acidic background electrolytes [77–80]. Due to
the commercial availability sulfated -CD and SBE--CD were evaluated. Initially, a 50 mM sodium
phosphate buffer, pH 2.5, containing a concentration of sulfated -CD between 5 and 30 mg/mL
was evaluated as background electrolyte. Upon applying a voltage of 15 or 20 kV under normal
polarity, none of the enantiomers could be detected. In contrast, the enantiomers were detected
upon reversing the polarity of the applied voltage (Fig. 15A).
Figure 15. Electropherograms of the separation of a non-racemic mixture of chloroquine (400
g/mL (R)-(–)-chloroquine ((R)-(–)-CQ) and 200 g/mL (S)-(+)-chloroquine ((S)-(+)-CQ)) using
sulfated -CD (A and B) and SBE(VII)--CD (C) as chiral selector. Experimental conditions: 50.2/40
cm, 50 m id fused-silica capillary, 20°C, 225 nm, (A) 50 mM sodium phosphate buffer, pH 2.5, 20
mg/mL sulfated -CD, –15 kV, (B) 100 mM sodium phosphate buffer, pH 2.5, 20 mg/mL sulfated -
CD, –15 kV and (C) 100 mM sodium phosphate buffer, pH 2.5, 20 mg/mL SBE(VII)--CD, –25 kV.


























However, peak broadening of the enantiomers was observed. Increasing the buffer molarity
resulted in sharp peaks and an improvement of the resolution (Fig. 15B). Injection of a sample
containing 2 mg/mL (R)-(–)-chloroquine and about 20 g/mL (S)-(+)-choroquine resulted in a
severely distorted peak of the minor enantiomer which could not be improved by increasing the
concentration of sulfated -CD or the buffer concentration or variation of the applied voltage.
Subsequently, SBE--CD with degree of substitution of 5 (DS 5) and 6.6 (DS 7) was evaluated.
The enantioseparation could not be achieved using SBE(V)--CD, whereas using SBE(VII)--CD
and revered polarity of the applied voltage resulted in a good resolution of the chloroquine
enantiomers (Fig. 15C). Reversal of the enantiomer migration order compared to sulfated -CD
was observed.
Finally, the concentration of SBE(VII)--CD was increased to 30 mg/mL, which allowed the
separation of a sample containing 3 mg/mL of (R)-(–)-chloroquine with acceptable peak shapes as
well as resolution and short migration times. Thus, the optimized conditions employed a 100 mM
sodium phosphate buffer, pH 2.5, containing 30 mg/mL SBE(VII)--CD as background electrolyte,
a 50 m id fused-silica capillary with an effective length of 40 cm, an applied voltage of –25 kV and
20°C capillary temperature. The analytes were detected at 225 nm. Carbamazepine was used as
internal standard due to its sharp peak and short migration time at about 6 min.
The optimized method was subsequently validated according to the ICH guideline “Validation of
analytical procedures”, Q2(R1). Method validation was performed using the chloroquine racemate.
Each enantiomer was validated over the range of 1.5-30 g/mL corresponding to 0.05-1% of the
minor enantiomer based on the concentration of 3 mg/mL of the major enantiomer. The LOQ
estimated at a signal-to-noise ratio of 10 was 0.05% (1.5 g/mL) for the enantiomers and the LOD
estimated at a signal-to-noise ratio of 3 was 0.02% (0.6 g/mL). Correlation coefficients of at least
0.997 were observed indicating sufficient linearity in the investigated concentration range. The RSD
values of intraday and interday precision at high and low concentrations were generally below 6%.
A synthetic sample of (R)-(–)-chloroquine was subsequently analyzed using the validated method.
An electropherogram of a sample containing 3 mg/mL (R)-(–)-chloroquine and 40 g/mL
carbamazepine as internal standard is shown in Fig. 16. A concentration of 0.24 ± 0.01% (mean ±
SD, n = 3) of the (S)-(+)-enantiomer could be detected as well as another impurity (peak X) at a
migration time of about 13 min. A concentration of another impurity 0.41 ± 0.02% was estimated by
peak area normalization. Peak X was not the synthetic precursor 4,7-dichloroquioline.
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Figure 16. Electropherogram of a sample containing 3 mg/mL (R)-(–)-chloroquine ((R)-(–)-CQ) with
about 0.3% (S)-(+)-chloroquine ((S)-(+)-CQ) as well as 40 g/mL carbamazepine (CBZ, IS) using
the optimized method. Experimental conditions: 50.2/40 cm, 50 m id fused-silica capillary,
100 mM sodium phosphate buffer, pH 2.5, 30 mg/mL SBE(VII)--CD, –25 kV, 20°C, 225 nm.
3.4 Generic method development and optimization of the stereoselective CE assay for the
determination of stereochemical purity of charged basic compounds and uncharged
compounds (Manuscript I, II, III, IV and V)
With regard to the present studies the development and optimization of CE methods for the
simultaneous separation of the major compounds and the corresponding minor chiral and achiral
compounds were achieved by various actions such as the variation of the compositions in the
background electrolyte, the buffer concentration and pH, type of CDs and modes of CE technique.
Thus, the factors affecting the enantioseparation as well as the general suggestions for method
development and optimization in order to separate the stereoisomers and related compounds
based on the present studies as described previously are discussed as follows.  Chiral compounds
containing basic functional group especially primary and secondary amines are most applicable.
3.4.1 Type of CDs
Initial screening tests employing various types of CDs are necessary. Due to the data obtained
form the five present studies the use of anionic CD derivatives, especially sulfated -CD and SBE-
-CD, shows a clear advantage over native CDs or neutral and positively charged CD derivatives.
Moreover, SBE--CD proved to be an effective chiral selector for both charged and uncharged
compounds. Samples containing very different contents of the major compound and minor analytes
should be used in order to evaluate the separation efficiency of the CD derivatives. For example,
the peak deformation of the minor enantiomer, (S)-(+)-chloroquine, was observed upon injection of










a sample of 2 mg/mL (R)-(–)-chloroquine and the peak deformation could be resolved by using
SBE(VII)--CD instead of sulfated -CD.
3.4.2 CD concentration
The variation of CD concentrations is used as one of the strategies in order to improve the
resolution and peak shape of investigated analytes. Generally, increasing the CD concentration
results in a good enantioresolution, but increasing the CD concentration above the maximum value
may result in an excess of electric currents and consequently a poor resolution due to Joule
heating generation as well. Therefore, there is an optimum CD concentration for a particular
compound at which chiral resolution reaches a maximum value. For example, in case of the CD-
modified MEEKC system the resolution of the amphetamine enantiomers was improved by
increasing the contents of sulfated -CD from 4% to 5.5%, but a further increase in sulfated -CD
above 6% resulted in a comigration of some peaks as well as an unstable baseline. Moreover, an
increase in the migration time with increasing concentrations of sulfated -CD was observed. The
effect of the CD concentration on the migration time depends on the charge of both, the chiral
selector and the analyte as well as the polarity of the applied voltage. In addition, an increase in the
CD concentration also affects the peak shape as shown in the case of the distorted peak of the
minor component levoamphetamine could be improved by increasing the concentration of HDAS--
CD.
3.4.3 A single CD system or a dual CD system?
In some case, it is preferable to combine two CDs in order to improve the enantioresolution of
chiral compounds when using a single CD is not effective. For example, a dual CD system
comprising SBE(V)--CD for the sufficient separation of uncharged compounds and sulfated -CD
for the effective resolution of the amphetamine enantiomers  proved to be superior to the use of a
single CD system.
3.4.4 Degree of substitution (DS)
It was noted that the degree of substitution of the CDs affects the resolution as well as peak shape
of analytes. In the case of SBE--CD with a DS of 4, 5 and 7, the baseline separation of
dexamphetamine and related compounds could be achieved by using SBE(V)--CD, whereas a
distorted peak of the major compound was observed for SBE(IV)--CD and a decrease in peak
resolution between the amphetamine enantiomers was observed for SBE(VII)--CD. Moreover, in
case of chloroquine the separation of the enantiomers could be achieved using SBE(VII)--CD
while SBE(V)--CD was insufficient. Thus, the enantioseparation of investigated compounds under
the variation of DS of the selected CDs should be also evaluated.
3.4.5 Batches of CD
In case of CDs with randomly substitution patterns or qualities, e.g., sulfated -CD, the qualities of
substituents in each batch affect the performance of the ananlytical method. On the other hand,
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batches of randomly substituted CD derivatives affect the reproducibility of the analytical methods.
As demonstrated in the separation of levodopa and related substances, three batches of
commercial sulfated -CD from different suppliers resulted in a different resolution, especially the
resolution between levodopa and Tyr as a critical pair.
3.4.6 Type of buffer and electrolyte
Based on the present studies sodium phosphate buffers seem to be most effective for the
stereoselective CE assay of basic compounds. In the case of levodopa and related substances, it
was noted that using a phosphate buffer prepared form orthophosphoric and sodium hydroxide
buffer molarity as well as the concentration of sulfated -CD could be reduced with comparable
separation to the use of a phosphate buffer prepared from sodium dihydrogen phosphate. In
addition, using Tris-phosphate buffers the observed electric currents are lower than using sodium
phosphate buffer.
3.4.7 Buffer concentration
The buffer concentration affects peak shape as well as resolution of analytes. Theoretically, the
adsorption of analytes to the capillary walls is reduced upon an increase in the buffer concentration
while an increase in ionic strength can reduce the electromigration dispersion, therefore the
separation and peak efficiencies are obtained [25, 51, 81]. In case of the analysis of
dexamphetamine employing HDAS--CD, an increase in the buffer concentration resulted in sharp
peaks of the later migrating levoamphetamine. Moreover, in case of the analysis of the chloroquine
enantiomers peak shape as well as resolution of the enantiomers was improved upon increasing
the buffer molarity from 50 mM to 100 mM. However, increasing the buffer concentration leads to
an increase in electric currents as well. With regard to the data obtained from the present CE
assays, the optimized methods frequently employ the phosphate buffer at concentrations between
50 and 100 mM.
3.4.8 Buffer pH
Buffer pH affects migration time as well as peak shape and resolution of the analytes. For example,
in case of the analysis of dexamphetamine employing HDAS--CD an increase in the buffer pH
from 2.5 to 3.5 and 6.5 led to shorter migration times but also poorer peak shape. As amphetamine
is a basic compound that is protonated at low pH increasing the interaction to CDs, therefore the
buffer pH can affect the migration time and the peak shape of analytes [30, 51]. However, the effect
of the buffer pH is sometimes unpredictable. For example, regarding the analysis of levodopa
reducing the buffer pH from 3.0 to 2.0 resulted in sharp peaks and short migration times. In case of
a dual CD system a partial overlap of the isomers of phenylacetone oxime could be resolved by
increasing the buffer pH from 2.5 to 3.0, but a longer migration time was observed. Furthermore,
the buffer pH affects the performance of the assay. For example, in case of the analysis of
dexamphetamine employing CD-modified MEEKC comigration and peak splitting were obtained
using a BGE at pH 9.5 whereas a sufficient resolution and peak shape could be achieved using
suppressed electroosmosis CD-modified MEEKC employing a BGE at pH 3.0. Based on the data
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obtained from the present CE assays, the optimized methods frequently employ the phosphate
buffer at pH between 2.0 and 3.0 for the separation of basic and neutral compounds.
3.4.9 Compositions in microemulsion and in the background electrolyte
In case an assay employing CD-MEEKC is selected, a variation of the composition of the
microemulsion and the BGE can be used to optimize the selectivity of the method. Initially, the
microemulsion consisting of 1.4 – 2% surfactant (e.g. SDS), 0.5 – 1% of an oil core (e.g. ethyl
acetate, n-heptane) and 3 – 4% co-surfactant (e.g. 1-butanol, 2-propanol, 1-pentanol) with or
without an organic modifier (e.g. 2-propanol, methanol, acetonitrile) should be evaluated. The
addition of CDs in order to accomplish stereoisomer separation should be subsequently evaluated
by screening of CDs and variation of CD concentrations. The buffer molarity and buffer pH used for
the preparation of microemulsion should be evaluated as well. Moreover, it was observed that the
addition of CD either before or after preparation of a microemulsion may affect the resolution of
analytes.
3.4.10 Normal polarity or reversed polarity?
Modes of the applied voltage, normal polarity and reversed polarity, affect the mobility and
consequently the separation of investigated compounds. The selection of normal or reversed
polarity depends on the performance which is generally due to the properties of the analyte and the
selected chiral selector. For example, in case of the analysis of dexamphetamine employing a dual
CD system none of neutral compounds could be detected using the normal polarity of the applied
voltage. In contrast, using the reversed polarity mode charged and neutral compounds could be
detected simultaneously. In addition, using the reversed polarity mode the BGE containing a high
concentration of CDs with electric currents below 100 A is allowed, which may result in an
improvement in the enantioseparation of analytes. For example, in case of the dual CD system
electric currents of about 75 A were observed when the optimized BGE containing the amount of
SBE(V)--CD as high as 80 mg/mL and 25 mg/mL sulfated -CD was employed. The superiority of
reversed polarity of the applied voltage was also observed for the analysis of the chloroquine
enantiomers employing SBE(VII)--CD as chiral selector. However, in case of the analysis of
dexamphetamine employing HDAS--CD and the example of levodopa the separation could be
achieved by using the normal polarity of the applied voltage.
3.4.11 Applied voltage
An increase in the applied voltage results in short analysis times. In some case the resolution is
also improved when the applied voltage is increased. However, increasing the applied voltage can
lead to excessive currents which result in Joule heating. With regard to the data obtained from the
present CE assays, the optimized methods frequently employed the applied voltage at between
+20 and +25 kV (normal polarity) or –10 to –25 kV (reversed polarity).
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3.4.12 Length of the capillary
Based on the data obtained from the present CE assays, the optimized methods were frequently
performed in a 50 m id fused-silica capillary with an effective length between 30 and 50 cm. A
decrease in an effective length of capillary generally results in a shot analysis time, however the
resolution may be reduced as well. In addition, an increase in electric currents was observed when
the effective length was shortened.
3.4.13 Temperature
An increase in temperature of the capillary generally gives rise to the electric current generation
and poor resolution. With regard to the data obtained from the present CE assays, the optimized
methods are frequently operated at a temperature between 15 and 20ºC.
3.4.14 Sample concentration and injected amount
An increase in the concentration of the major compound as well as an increase in the injection time
can be used in order to enable the determination of impurities at the 0.1% level or below. However,
peak deformation or peak tailing of the major compound as well as a partial overlap of the
enantiomers can be also observed due to an increase in sample concentration as well as long
injection times. Based on the data obtained from the present CE assays, a hydrodynamic injection
at a pressure of 0.5 psi for 4 to 8 sec is usually employed in the optimized method.
3.4.15 Preconditioning of the capillary
Preconditioning of the capillary before sample introduction may affect the stability of the baseline
as well as the resolution and the peak shape of the analytes. A 0.1 M sodium hydroxide solution is
commonly used for the preconditioning process followed by water and either the BGE or the buffer
(no CD). In case of CD-modified MEEKC methanol is usually included in the preconditioning
process. Interestingly, regarding the analysis of the chloroquine enantiomers the use of the BGE in
preconditioning led to currents above 100 A as well as a poor resolution. In contrast, using the
buffer without CD in preconditioning resulted in a good resolution of the chloroquine enantiomers
and currents between 80 and 90 A were observed.
3.4.16 Schematic guidance for method development and optimization
Based on the data obtained from the present stereoselective CE assays for the simultaneous
determination of various phenylethylamine derivatives as well as related charged and neutral
compounds, different strategies used for achieving chiral and non-chiral separation are purposed.
A generic guidance for development and optimization of a CE method for the determination of
stereochemical purity and related impurities is shown in Fig. 17 as a schematic flow chart. The
guidance in Fig. 17 is adapted from the guidance published by Sokoließ and Köller [82].
Compounds containing basic functional group, especially primary and secondary amines, as well
as neutral functionalities are most applicable for this guidance. In addition, in case of the
chloroquine enantiomers the method development and optimization was conducted according to
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this guidance, thus a short time was spent in order to accomplish the enantioseparation of
(±)-chloroquine.
Figure 17. Guidance on development and optimization of CD-mediated CZE and CD-modified
MEEKC methods for the simultaneous determination of stereochemical purity and related
compounds of basic drugs (adapted from Ref. [82]).
1. Properties of the analyte
• pKa
• Solubility (if possible up to 2 – 5 mg/mL)
• Solvent (water; buffer; possibly mixtures with organic
solvents)
• UV absorbance
CD-mediated CZE CD-modified MEEKC
fails
2.b Screening of microemulsion (ME) system
• microemulsion: 1.4 – 2% surfactant (e.g., SDS),
0.5 – 1% of an oil core (e.g., ethyl acetate, n-
heptane) and 3 – 4% co-surfactant (e.g., 1-
butanol, 1-pentanol) with or without an organic
modifier (e.g., 2-propanol, methanol, acetonitrile)
• Buffer:
1). 20 – 50 mM sodium phosphate buffer,
pH between 2.0 and 3.0,
2). 20 – 50 mM sodium phosphate buffer, pH 6.5,
3). If 1+2 fails, 5 – 20 mM sodium borate buffer,
pH 9.2
• Current: not more than 100 A
2.a Screening of cyclodextrins
• BGE: 5 – 20 mg/mL CDs (if fails, use 30 – 80 mg/mL CDs with
currents below 100 A) in a 50 – 100 mM sodium phosphate
buffer,
pH 2.0 (if pH 2.0 fails, try at pH 4.5, and pH 7.0)
• Cyclodexrtrin: 1). negatively charged CD derivatives (start with
sulfated -CD, SBE- -CD) 2). if 1 fails, try native CDs, neutral and
other charged CD derivatives
• Conditions: 50 m id uncoated fused-silica capillary, 50.2/40 cm,
+20 kV or –10 kV, 20ºC
analyte concentration 1 mg/mL,
injection: Hydrodynamically 0.5 psi * 4 sec,
analysis time: 60 min
• Current: not more than 100 A
2.c Screening of CDs in CD-modified MEEKC system
• BGE: microemulsion and 2 – 8% CDs
• Cyclodexrtrin: 1). negatively charged CD derivatives (start
with sulfated -CD) 2). if 1 fails, try native CDs, neutral and
other charged CD derivatives
• Order of mixing: add CDs before or after ME preparation
• Conditions: 50 m id uncoated fused-silica capillary,
50.2/40 cm, +20 kV or –10 kV, 20°C
analyte concentration:1 mg/mL
injection:Hydrodynamically 0.5 psi * 4 sec
analysis time: 60 min
3. Selectivity optimization
• pH
• type and concentartion of electrolyte
• concentration of chral selector
• degree of substitution and batches of
    CDs
• single or dual CD system
• applied voltage
• injection time




• accorrding to the ICH
guildeline Q2(R1)
5. Drug analysis




The stereochemical configuration of drugs plays an important role for their biological activities due
to the stereoselectivity of enzymes, receptors and other molecular targets. This is also reflected in
the fact that single enantiomer drugs have become a significant proportion in worldwide drug sales.
Generally, the safety and efficacy of a drug does not only depend on the active ingredient itself but
also on impurities. In case of chiral drugs the distomer has to be considered as well. Therefore, the
control of the enantiomeric purity of a drug substance as well as the related substances is an
important concern of pharmaceutical companies and regulatory authorities. Traditionally,
polarimetry is used for the determination of the enantiomeric purity while HPLC is applied to the
determination of related substances. In recent years CE has been acknowledged as a powerful
technique allowing the analysis of closely related structures as well as stereoisomers. Therefore,
the aim of the thesis was the development and validation of stereoselective CE assays allowing the
simultaneous determination of related substances as well as enantiomeric purity of chiral drugs.
The single enantiomer drugs dexamphetamine and levodopa as well as the racemic drug
chloroquine were selected as target analytes. CDs were employed as chiral selectors because they
are most widely used in CE enantioseparations.
Three different CE assays were developed and validated for the analysis of dexamphetamine
including a single CD system, a dual CD system and a CD-modified MEEKC method. The initially
developed single CD method allowed the determination of the charged potential impurities 1R,2S-
(–)-norephedrine and 1S,2S-(+)-norpseudoephedrine besides the analysis of the enantiomeric
purity. Heptakis-(2,3-di-O-acetyl-6-O-sulfo)-β-CD (HDAS-β-CD) was chosen as chiral selector
based on a screening of neutral and charged CD derivatives. The assay was subsequently
validated employing 1R,2S-(–)-ephedrine as internal standard. Analysis of commercial samples
dexamphetamine sulfate drug substance revealed the presence of 2.8 - 4.0% of the levorotatory
enantiomer but none of the charged impurities could be detected. Apparently, dexamphetamine is
not synthesized from the chiral precursors.
Therefore, a second assay allowing also the determination of neutral synthetic precursors such as
phenylacetone and phenylacetone oxime was developed and validated. Following a screening of
neutral and negatively charged CDs, sulfated -CD and sulfobutylether -CD with degree of
substitution of 5 (SBE(V)--CD) were selected due to their abilities for the separation of both
charged and neutral compounds. In the dual CD system sulfated -CD effectively separated the
amphetamine enantiomers while SBE(V)--CD resolved the related charged and uncharged
substances. The present assay was able to separate the geometrical isomers E- and Z-isomers of
phenylacetone oxime. As observed for the single CD assay neither 1R,2S-(–)-norephedrine nor
1S,2S-(+)-norpseudoephedrine could be detected. In contrast, phenylacetone as well as the E- and
Z-isomers of phenylacetone oxime could be detected indicating the synthetic origin of the samples.
The distomer levoamphetamine was detected as well.
Finally, a CD-modified MEEKC assay was developed and validated as an alternative method. The
background electrolyte consisted of the microemulsion containing sodium dodecyl sulfate (SDS),
ethyl acetate, 1-butanol, 2-propanol and a 50 mM sodium phosphate buffer. The chiral selector was
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sulfated -CD. The effects of the composition of the microemulsion, the CD concentration, the
buffer concentration, the buffer pH and the applied voltage on the resolution of all analytes were
investigated. Interestingly, the addition of sulfated -CD to the BGE either before or after the
preparation of the microemulsion slightly affected the resolution of some analytes. The method was
validated using carbamazepine as internal standard. Subsequently, commercial samples of
dexamphetamine sulfate were analyzed. Only levoamphetamine could be detected due to the fact
that the LOD of the MEEKC method was higher compared to the single or dual CD assays.
Comparing the three CE assays, the dual CD method was superior due to its ability to allow the
analysis of charged and uncharged compounds as well as due to the low LOD. A clear
disadvantage is the use of expensive SBE(V)--CD in the assay.
The stereoselective CE assay developed for levodopa used sulfated -CD at a concentration of 6
mg/mL in a 0.1 M sodium phosphate buffer, pH 2.0. The method was validated using L-
phenylalanine as internal standard. Three samples of commercial levodopa drug substance were
subsequently analyzed. Neither 6-hydroxy-DOPA nor 3-methoxy-L-tyrosine could be detected in
the samples, whereas L-tyrosine was detected in all samples at concentrations below the LOQ. D-
DOPA was found in two samples.
Finally, a stereoselective CE assay was developed and validated in order to determine the
enantiomeric purity of synthetic R-(–)-chloroquine. The method was initially developed and
optimized using sulfated -CD as a chiral selector. However, upon an injection of a sample
containing 2 mg/mL R-(–)-chloroquine peak deformation of the minor component S-(+)-chloroquine
was observed. Peak distortion could be avoided using SBE(VII)--CD as chiral selector, which also
allowed to increase the sample concentration to 3 mg/mL. Carbamazepine was used as internal
standard. Upon analyzing a synthetic sample of R-(–)-chloroquine, S-(+)-chloroquine was found at
a concentration of 0.24% ± 0.01% (means ± SD). Moreover, an unknown impurity with a shorter
migration time was also detected at the 0.4% level calculated from normalized peak area.
In conclusion, the methods developed in the thesis proved the applicability of CE for the
simultaneous determination of the enantiomeric purity and related substances of the drugs
dexamphetamine, levodopa and chloroquine. The assays had acceptable peak efficiency,
sensitivity and precision. Moreover, they could be used to analyze commercial samples. Thus, the
method could be considered valuable alternatives to the current methods used by the European
Pharmacopoeia or the United States Pharmacopeia.
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Zusammenfassung
Die stereochemische Konfiguration von Arzneistoffen beeinflusst ihre biologische Aktivität aufgrund
der stereoselektiven Interaktion mit Enzymen, Rezeptoren und anderen molekularen Targets. Dies
zeigt sich auch in der Tatsache, dass enantiomerenreine Arzneistoffe einen signifikanten Anteil an
den weltweiten Pharmaumsätzen besitzen. Die Sicherheit und Effizienz von Arzneistoffen wird
nicht nur vom Wirkstoff sondern auch von Verunreinigungen bestimmt. Im Fall enantiomerenreiner
Arzneistoffe muss das Distomer auch als Verunreinigung angesehen werden. Daher ist die
Bestimmung der Enantiomerenreinheit für Pharmaunternehmen und Zulassungsbehörden von
großer Bedeutung. Traditionellerweise wird die Enantiomerenreinheit mittels Polarimetrie bestimmt,
während verwandte Substanzen mittels HPLC begrenzt werden. In den letzten Jahren hat sich die
Kapillarelektrophorese (CE) als eine Analysentechnik zur Bestimmung nahe verwandter
Substanzen einschließlich Stereoisomeren entwickelt. Daher war das Ziel der Forschungsarbeiten
die Entwicklung und Validierung stereoselektiver CE Verfahren, die die simultane Bestimmung
verwandter Substanzen und der Enantiomerenreinheit chiraler Arzneistoffe erlauben.
Als Substanzen wurden die chiralen Wirkstoffe Dexamphetamin und Levodopa ausgewählt sowie
der racemische Arzneistoff Chloroquin. Als chirale Selektoren wurden Cyclodextrine (CDs) als die
für chirale Trennungen am häufigsten eingesetzten Selektoren eingesetzt.
Für Dexamphetamin wurden 3 CE Assays entwickelt und validiert-ein Verfahren unter Verwendung
eines CDs, ein Verfahren mit dualem CD System sowie ein Verfahren mittels CD-modifizierter
Mikroemulsion elektrokinetischer Chromatographie (MEEKC). Das zuerst entwickelte Verfahren mit
einem CD erlaubt die Bestimmung der geladenen Verunreinigungen 1R,2S-(–)-Norephedrin und
1S,2S-(+)-Norpseudoephedrin sowie die Bestimmung der Enantiomerenreinheit. Als chiraler
Selektor wurden Heptakis-(2,3-Di-O-acetyl-6-O-sulfo)-β-CD (HDAS-β-CD) eingesetzt. Der Assay
wurde mit Ephedrin als internem Standard validiert. In kommerziellen Proben wurden 2.8 bis 4.0%
des linksdrehenden Amphetamin-Stereoisomers gefunden. Keine der geladenen Verunreinigungen
konnte nachgewiesen werden, so dass von einem anderen Syntheseweg als über die Naturstoffe
ausgegangen werden muss.
Daher wurde ein zweiter Assay entwickelt und validiert, der auch die Bestimmung neutraler
Synthesevorstufen Phenylaceton und Phenylacetonoxim erlaubt. Nach einem Screening wurden
sulfatiertes -CD und Sulfobutylether--CD mit einem Substitutionsgrad von 5 (SBE(V)--CD)
aufgrund ihrer Trenneigenschaften ausgewählt. In dem dualen CD-System erfolgt die
Enantiomerentrennung des Amphetamins in erster Linie durch das sulfatierte -CD, während die
Trennung der geladenen und ungeladenen verwandten Substanzen durch SBE(V)--CD erfolgt. In
dem Assay werden auch die E- und Z-Isomere des Phenylacetonoxims getrennt. Wie im ersten
Assay konnten die geladenen potentiellen Verunreinigungen nicht nachgewiesen werden, aber es
wurden Peaks des Phenylacetons und der Oxim-Stereoisomere gefunden. Dies belegt die
Synthese der Substanz. Levoamphetamin wurde ebenfalls gefunden.
Zusätzlich wurde eine CD-modifizierte MEEKC-Methode als alternatives Verfahren aufgebaut. Der
Hintergrundelektrolyt bestand aus einer Mikroemulsion aus Natriumdodecylsulfat (SDS),
Ethylacetat, 1-Butanol, 2-Propanol und 50 mM Natriumphosphat-Puffer. Der chirale Selektor war
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sulfatiertes -CD. Die Zusammensetzung der Mikroemulsion, die CD Konzentration, die
Pufferzusammensetzung, der Puffer pH sowie die angelegte Spannung wurden optimiert.
Interessanterweise hatte der Zeitpunkt der Zugabe des CDs (vor oder nach Herstellung der
Mikroemulsion) einen Einfluss auf die Auflösung einiger Peaks. Nach der Validierung unter
Verwendung von Carbamazepin als interner Standard wurden Substanzproben vermessen.
Aufgrund der geringeren Nachweisgrenze verglichen mit dem dualen CD-Assay konnten außer
Levoamphetamin keine anderen Verunreinigungen nachgewiesen werden.
Im Vergleich der 3 Methoden erwies sich der Assay mit dualem CD-System als universeller und
sensitiver zur Bestimmung der untersuchten potentiellen Verunreinigungen. Allerdings ist SBE(V)-
-CD teuer.
Bei der stereoselektiven Methode für Levodopa wurde wiederum sulfatiertes -CD als chiraler
Selektor in einer Konzentration von 6 mg/mL in 0.1 M Natriumphosphatpuffer mit pH 2.0
eingesetzt. L-Phenylalanin diente als interner Standard. Bei der Untersuchung von 3
Substanzproben konnte von den im Europäischen Arzneibuch aufgeführten Nebenprodukten
weder 6-Hydroxy-DOPA noch 3-Methoxy-L-tyrosin nachgewiesen werden, während L-Tyrosin in
allen Proben unterhalb der Bestimmungsgrenze detektiert wurde. 2 Proben enthielten auch geringe
Mengen an D-DOPA.
Zur Bestimmung der Enantiomerenreinheit von synthetischem R-(–)-Chloroquin wurde ursprünglich
ein Verfahren unter Verwendung von sulfatiertem -CD untersucht. Nach Injektion einer Probe vom
R-(–)-Chloroquin mit einer Konzentration von 2 mg/mL wurde die Deformation des Peaks des in
geringer Konzentration vorhandenen  S-(+)-Chloroquin beobachtet. Daher wurde sulfatiertes -CD
durch SBE(VII)--CD ersetzt, was gleichzeitig die Erhöhung der Konzentration der Probe auf 3
mg/mL erlaubte. Carbamazepin diente als interner Standard. Der Anteil an S-(+)-Chloroquin in
einer Probe R-(–)-Chloroquin betrug 0.24% ± 0.01% (Mittelwert ± SD). Außerdem wurde eine
zusätzliche unbekannte Substanz im Bereich von 0.4% nach Normalisierung gefunden.
Zusammenfassend kann festgestellt werden, dass die im Rahmen der Forschungsarbeiten für
Dexamphetamin, Levodopa und Chloroquin entwickelten CE Methoden zur simultanen
Bestimmung der Enantiomerenreinheit und der verwandten Substanzen geeignet sind. Die
Verfahren besitzen ausreichende Effizienz, Sensitivität und Präzision. Kommerzielle
Substanzproben konnten untersucht werden. Daher können die neuen Verfahren Alternativen zu
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